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a b s t r a c t
Nanocrystalline calcium phosphate apatites constitute the main
inorganic part of hard tissues, and a growing focus is devoted to
prepare synthetic analogs, so-called “biomimetic”, able to precisely
mimic the morphological and physico-chemical features of bio-
logical apatite compounds. Both from fundamental and applied
viewpoints, an accurate characterization of nanocrystalline
apatites, including their peculiar surface features, and a deep
knowledge of crystallization aspects are prerequisites to attempt
understanding mineralization phenomena in vivo as well as for
designing innovative bioactive materials that may then find
applications in bone tissue engineering, either as self-supported
scaffolds and fillers or in the form of coatings, but also in other
domains such as drug delivery or else medical imaging. Also,
interfacial phenomena are of prime importance for getting a better
insight of biomineralization and for following the behavior of
biomaterials in or close to their final conditions of use. In this view,
both adsorption and ion exchange represent essential processes
involving the surface of apatite nanocrystals, possibly doped with
foreign elements or functionalized with organic molecules of
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interest. In this review paper, we will address these various points
in details based on a large literature survey. We will also underline
the fundamental physico-chemical and behavioral differences that
exist between nanocrystalline apatites (whether of biological
origin or their synthetic biomimetic analogs) and stoichiometric
hydroxyapatite.
1. Introduction
Nanocrystalline calcium phosphate apatites play an important role in biomineralization and in the
biomaterials field. Biological nanocrystalline apatites are the main inorganic components of hard
tissues in mammals (bone and tooth, with the exception of enamel which is closer to stoichiometric
hydroxyapatite) and are involved in several pathological calcifications such as dental calculi, salivary
stones, blood vessel calcification, etc [1–5]. In comparison with hydroxyapatite [HA, Ca10(PO4)6(OH)2]
which is a stoichiometric apatitic phase that is the most stable and least soluble calcium phosphate at
ambient conditions, nanocrystalline apatites are nonstoichiometric, calcium- (and OH-) deficient and
may incorporate substituted ions in their nanosized crystals. Their calcium and hydroxide deficiencies
are responsible for a higher solubility than HA. Besides, they have the property of being able to mature
when submitted to humid environments [5]. Due to this maturation process, “mature” bone crystals for
vertebrates are less soluble and reactive than embryonic bone mineral crystals [6]. The small size and
nonstoichiometry of apatite nanocrystals fulfill an important biological function in bone since they
presumably bestow the mineral phase with the solubility needed for resorption of the bone by oste-
oclasts (bone resorbing cells), and enable bone mineral to act as an ion “reservoir” capable of either
capturing or releasing ions (or small molecules) under the control of the body for ensuring homeo-
stasis. Owing to these special properties, bone is thus a living tissue, far from being inert, which
continuously undergoes remodeling and repair processes [7]. In addition, nanocrystalline apatites play
a decisive role in the biological activity of implants (biomaterials) since the formation of a nano-
crystalline bonelike apatite layer in their surface, when immersed in a simulated body fluid solution,
can determine whether these materials can adequately integrate into the host living tissue [8].
Synthetic apatites exhibit excellent biological properties such as biocompatibility, bioactivity, lack
of toxicity or inflammatory and immunitary responses, and also a relatively high bioresorbability.
These properties can be significantly enhanced by improving their biomimetism [9], that is, by
preparing themwith similar dimensions, morphology, (nano)structural and chemical characteristics as
for biological ones. Many different synthetic strategies have been employed to prepare nanosized
apatite crystals [5]; however, the preparation of actually biomimetic nanocrystalline apatites may still
be seen as a scientific and technological challenge [10]. It is important to underline thatmost important
characteristics conferring the special properties to nanocrystalline apatites are the nanosized
dimensions, their large surface-to-volume ratio, and the existence of a surface hydrated layer, non-
apatitic in nature, which is essentially related to the formation process in solution. In fact this layer
is bound to progressively disappear as the stable apatite domains (in the core of the crystals) develop
with time (so-called maturation process). This hydrated layer exhibits a great ionic mobility, as well as
ion exchange and adsorption capacities, and could participate in the interaction with macromolecules
and drugs [4]. Thus, as mentioned above, this layer on bone mineral nanocrystals is thought to actively
participate in homeostasis and other regulation processes [6]. Because of their excellent physico-
chemical and surface properties, nanocrystalline apatites then found applications as bio-inspired
apatite-based bioceramics for bone substitution, repair or augmentation, or else as carrier vehicles
for proteins, drugs and gene delivery [4,11] or even in medical imaging.
The present paper reviews the recent progresses on the preparation of nanocrystalline apatites with
tailored surface properties, which are based on the exploitation of their surface hydrated layer (as for
biological apatites), as well as the characterization of nanocrystals surfaces and surface interactions
with ions and macromolecules.
The review is structured in five sections. Section 1 is devoted to the description of biologically-
related calcium phosphates and in particular to the recent studies and findings in terms of bio-
mineralization related to the formation of bone and teeth. Section 2 deals with the latest published
works regarding the preparation and crystallization mechanisms of biomimetic apatites with tailored
surfaces properties. In Section 3 we report on the recent advances in the characterization of nano-
crystalline apatite surfaces and their interactions with macromolecules and ions, of superior impor-
tance regarding their biological activity. Finally, Section 4 reviews some of the main advanced
biomedical applications, related in particular to the emerging field of nanomedicine such as medical
imaging, the setup of nano-carriers for drugs, proteins and gene delivery, or else bioactive coatings of
metal implants.
Based on this review of the state-of-the-art in relation with biomimetic nanocrystalline apatites,
there are excellent and exciting perspectives for the development of advanced bioactive bioceramics
for bone tissue engineering, as well as for the setup of biomimetic nanoparticles with new applications
based on the tailoring of their surface properties, for example by functionalizing the surface of the
nanocrystals with specific molecules and ions or by using them to produce multifunctional engineered
nanoparticles.
2. Biologically-related calcium phosphates and recent advances in biomineralization related to
bone and tooth formation
As previously explained, in biological systems, calcium phosphates are the principal inorganic
constituent of normal (bones, teeth, fish enameloid, deer antlers and some species of shells) and
pathological (dental and urinary calculus and stones, atherosclerotic lesions) calcifications. Except for
small portions of the inner ear, all hard tissues of the human body are formed of calcium phosphates.
Structurally, with the exception of enamel, they occur in the form of poorly crystallized non-
stoichiometric and carbonate-substituted nanocrystalline apatites [12,13].
2.1. Bone mineralization
Bones are rigid organs that form part of the endoskeleton of vertebrates. Their function is to move,
support and protect the various organs of the body, produce red and white blood cells and store
minerals [14,15]. Bones appear in a variety of shapes and have a complex internal and external
structure; they are lightweight, yet strong and hard, in addition to satisfying their many other func-
tions. Bone is a hierarchically-structured biomineral that has captivated scientists because of its
particular structure and unique mechanical properties and remodeling capability. To understand its
complex architecture, several hierarchical models have been proposed. The most known is the model
of Weiner and Wagner [16] who described seven levels of hierarchy that range from the nanoscale to
the macroscopic scale (Fig. 1).
The first level consists of molecular and crystalline components such as collagen, apatite, water and
the rest of molecules. The second level is formed by the mineralized collagen fibrils. The third level is
composed of arrays of mineralized collagen fibrils. These fibrils are almost always associated as bundles
or other arrangements, often aligned along their long axis. The fourth level is composed of the different
patterns of fibril arrays. These patterns can be parallel arrays, woven arrangements, plywood like
structures, and radial arrays. Cylindrical structures called osteons make up the fifth level. The sixth
level is formed by spongy (trabecular or cancellous) or compact (cortical) bone tissues. Cancellous bone
is extremely porous (75–95 wt.% porosity) and provides space for marrow and blood vessels, but has
much lower compressive strength. Cortical bone is otherwise the dense outer layer (5–10 wt.%
porosity) that allows many functions of bone. The seventh level is simply the whole bone. S. Mann
presented a similar structural hierarchy containing six levels [1].
Bone is made of about 65 wt.% of mineral phase (nanosized crystals of apatite), 25 wt.% of organic
phase (basically type-I collagen, non-collagenous proteins (NCPs), minor organic molecules such as
citrate) and 10 wt.% of water [2,11,16]. Apatite nanocrystals are calcium- (and hydroxide-) deficient,
with a ratio of Ca/P< 1.67, which is the theoretical value for the stoichiometric hydroxyapatite mineral
(Ca10(PO4)6(OH)2). Other interesting features of bone apatite are the poor crystallinity degree, the
presence of ionic substituents in its crystalline structure (4–6 wt.% carbonate, 0.9 wt.% Na, 0.5 wt.% Mg
and others) and a typical plate-like morphology. The reported dimensions of nanocrystals vary
according to the technique employed (Table 1). Using TEM, XRD and SAXS, the characterized dimen-
sions vary in the following ranges: length (20–50 nm), width (15–30 nm) and thickness (1.5–4 nm)
[2,17–21]. Studies by AFM, however, found that widths and lengths of bone crystals range from 30 to
200 nm [1]. Although apatite nanocrystals are usually presented as an inert single chemical compound
with a passive role in the mechanical properties of bone, it must be underlined that the nanocrystals
fulfill in fact a biological role, including through the “ion reservoir” function. It is thought that theymay
participate actively in homeostasis. This role has been attributed to their very high surface area and to
Fig. 1. Sevenhierarchical levels of bone organization. Reprintedwith permission fromRef. [13]. Copyright 2010DoveMedical Press Ltd.
Table 1
Characterization of bone crystallites dimensions using different analytical methods.
Analytical method Crystal dimensions
TEM 20 nm long # 3–6 nm wide
XRD 10–35 nm long
mXRD (14–17) nm # (3–5) nm
SAXS 50 nm # 25 nm # 1.5–4 nm
SAXS and TEM 30 nm # 20 nm # 1.5–2 nm
AFM (200–30) nm # (200–30) nm # (3–10) nm
the presence of a hydrated surface layer with strong abilities for ion exchange and adsorption of
organic molecules. Due to their variable and complex composition, biological apatites were sometimes
considered as a mixture of phases, which in consequence can be characterized by X-ray diffraction
techniques. However, these techniques cannot provide information on the fine structural details of
their surface. Recent progress onwet surface characterization of synthetic nanocrystalline apatites has
occurred thanks to the use of spectroscopic methods. The data obtained by FTIR and solid state NMR
revealed that freshly precipitated nanocrystals show specific lines that are lost after drying and are
assigned to the existence of a hydrated structured surface layer, non-apatitic in nature. Some of their
spectroscopic features are surprisingly analogous to those of triclinic octacalcium phosphate (noted
OCP or, more precisely, OCPt). This layer becomes progressively transformed into the more stable
apatitic lattice upon maturation in aqueous media. On the other hand the loosely-bound ions of this
layer can be easily and reversibly substituted. Another feature is that the adsorption properties and
reactivity of nanocrystalline apatites strongly depend on the composition of this layer [22].
Besides the above surface features, it is generally assumed that the very small particle size and the
nonstoichiometry are bulk physicochemical features that presumably bestow the mineral phase with
the solubility needed for resorption of the bone by osteoclasts, while their small thickness favors the
mechanical properties, likely preventing crack propagation. Recently, citrate molecules strongly bound
to the nanocrystalline apatite surfaces (1 molecule per every 2 nm2) have been identified by advanced
solid-state NMR and proposed to be responsible for the inhibition of crystal thickening and also for the
stabilization of nanocrystals within the collagen matrix [23]. NMR studies have revealed that citrate
represents 5.5 wt.% of the organic matrix of bone [23]. Due to its excellent chemical and biochemical
properties, like its excellent Ca-complexing power and its bioavailability, some authors of the present
review employed citrate molecules for the preparation of synthetic apatite nanoparticles that incor-
porated the molecules to their surfaces [24].
In addition to the recent interest for the characterization of surface properties of bone nanocrystals,
the mineralization of collagen (the second level of hierarchy) has been the subject of intense inves-
tigation during the last decade. In this respect the description of bone nanostructure deserves some
few words. Bone nanostructure is made of a self-assembled fibrillar collagen matrix mineralized with
oriented apatite nanocrystals at both intrafibrillar and interfibrillar zones. During bone formation the
collagen molecules self-assemble into triple helical structures called tropocollagen. The interaction
between tropocollagen units leads to self-organization into fibrillar structures. Type I collagen mole-
cules assemble their tropocollagen units giving rise to holes and overlapping areas that can be
observed as a periodic banding pattern along the 67 nm repeat and a less dense 40 nm-long gap zone
(when stained for observation by TEM), the so-called D-band pattern (Fig. 2).
The holes appear mineralized and forming mineral bridges between them. The non-collagenous
proteins (NCPs) appear linked to collagen and close to the mineralization front. Most of them are
polyanionic and hold high amounts of carboxylate and phosphates groups which are arising from
phosphoserine and aspartic and glutamic residues, with high affinity for Ca ions [26].
Duringmany years therewas controversy onwhether it is collagen or NCPs that initiate intrafibrillar
mineralization and on the mechanisms producing it at molecular level. It was thought that NCPs, while
bonded to collagen fibers, could act as promoters of intrafibrillar nucleation. Such a hypothesis was
supported by reports showing that NCPs appear during the formation of new bone in a very specific
spatiotemporal timeline [27] and also that type-I collagen alone, dissociated from NCPs, is unable to
produce bone mineralization [28]. On the other hand, it was proven that NCPs such as osteopontin,
vitronectin and albumin, when they are dissociated from collagen, are inhibitors of calcium phosphate
nucleation in solution [29–31].
Recently, in vitro intrafibrillar mineralization of collagen was achieved by substituting NCPs with
polyaspartic acid (pAsp) [7,32]. Price et al. [33] proposed amechanism for fibril mineralization based on
inhibitor exclusion, by which macromolecular inhibitors of apatite growth favor fibril mineralization
by selectively inhibiting crystal growth in the solution outside of the fibril. These authors tested this
mechanism by using fetuin, a 48-kDa inhibitor of apatite growth. In the absence of fetuin, mineral
growth occurred primarily in the solution outside of bone collagen, whereas in the presence of fetuin,
mineral growth occurred almost exclusively within bone collagen. Only very recently, in 2010, the
group of Sommerdijk [34] based on previous results [7,32] has shown that collagen functions in
synergy with inhibitors of hydroxyapatite nucleation to actively control mineralization by a mecha-
nism of electrostatic interactions. These researchers used cryo-TEM and cryogenic electron tomog-
raphy with molecular modeling to study this phenomenon and to follow the mineralization
mechanism. In their experiments, Sommerdijk’s group used type-I collagen and either polyaspartic
acid (pAsp) or fetuin instead of NCPs as soluble inhibitors macromolecules. According to their results
amorphous calcium phosphate (ACP) nucleate on polyaspartic acid forming negatively-charged ACP-
pAsp complexes. The mineral infiltration inside the fibrils is promoted by the net positive charge close
to the C-terminal region of the collagen molecules at the gap and overlap areas. Furthermore, the
charged aminoacids in these zones form nucleation sites controlling the conversion of ACP into
a parallel array of oriented apatite nanocrystals. Although there are some open questions such as the
role of the citrate molecules in this process, that could explain how these molecules participate in the
biological regulation of nanocrystalline apatite formation, it can be said that these investigations have
opened the door to the fabrication of intra-mineralized collagen bone analogs.
2.2. Teeth mineralization
Teeth consist of a bulk of dentin covered with (inorganic) enamel on the crown and cementum on
the root surface [35]. Thick collagen bundles, called periodontal ligaments (PDL), attach to cementum
at one end and the alveolar bone at the other end. The alveolar bone is supported by the jaw. These
mineralized tissues are deposited by cells differentiating through interactions between inner neural
crest-derived ectomesenchymal cells and overlying epithelial cells. Dentin and bone are similar in
inorganic content (about 70 wt.% and 67 wt.%, respectively), crystal size and crystallinity and organic
composition, including the type-I and type-V collagen heterofibril framework [36,37], but these two
Fig. 2. Cryo-TEM images of (A) loosely packed collagen bundle (arrow, 1) and fully assembled fibril (arrowhead, 2) at pH 7.4. Scale
bar: 100 nm. (B) Assembled fibril showing clear D-band pattern. The dashed rectangle indicates the area used to calculate the
profiles depicted in (C). (C) Intensity profile of the collagen fibril along the long axis, showing D-band pattern. Reprinted with
permission from Ref. [25]. Copyright 2011 Royal Society of Chemistry.
tissues are histogenetically different. Dentin is characterized by closely-packed tubules extending
throughout its entire thickness. These tubules contain cell processes of odontoblasts (dentin-forming
cells), and their cell bodies are typically aligned along the inner edge of dentin, the dental pulp [35]. In
contrast, bone usually has cells (osteocytes) within the matrix and either active or quiescent bone-
forming cells (osteoblasts) on the surface. On the contrary, enamel is distinct from bone and dentin
in its tissue origin, mineralization matrix, and mode of mineralization [38]. Enamel is the hardest
materials and with most robust mechanical properties formed by vertebrates and it is the most highly
mineralized skeletal tissue present in the body. Mature enamel is composed of 95–97 wt.% carbonated
HA with less than 1 wt.% organic material. Compared to dentin, enamel is uniquely composed of
extremely long and narrow crystals (around 100 mm # 50 mm, [39]), packed into parallel arrays, called
enamel rods, which can form intricate interwoven patterns. The high degree of mineralization makes
enamel a fascinating model for understanding fundamental mineralization processes and processes
that occur within an extracellular matrix. It is distinct from bone in terms of architecture, pathology
and the biological mechanisms mediating its formation [40]. Additionally, unlike other biomineralized
tissues, mature enamel is acellular and does not resorb or remodel. As a result, enamel regeneration
cannot occur in vivo following failure and is therefore an attractive target for future biomimetic and
therapeutic approaches.
Enamel formation, or amelogenesis, is a highly regulated process involving precise genetic control
as well as protein–protein interactions, protein–mineral interactions, and interactions involving the
cell membrane. Enamel forms by HA crystallization on a non-collagenous protein matrix secreted from
ameloblasts of epithelial origin, whereas bone and dentin form on a collagenous matrix deposited by
cells of mesenchymal origin. The enamel matrix mineralizes immediately after secretion [41]. During
the initial stages (secretory stage) of enamel formation, long thin ribbons of enamel mineral are formed
almost immediately as the ameloblast lays down enamel matrix proteins [42,43], suggesting that
enamel mineralization does not take place within a preformed matrix [41]. This process is in sharp
contrast to bone and dentin, both of which mineralize on preformed unmineralized matrix, called
osteoid and predentin respectively. Although these mineral ribbons are extremely long (>100 mm) and
may extend the full thickness of the enamel layer [39,44], they are only a few unit cells thick (i.e., in the
order of 10 nm) [45,46], if the initial mineral phase is considered to be HA or OCP. The c-axis of these
crystals always coincides with their long axis [47], whereas, a- and b-crystallographic axes coincide
with two other (thickness and width) morphological axes of the crystal. The mineral phase of secretory
enamel is approximately 10–20 vol.%, with the remaining portion occupied by matrix protein and
water [48]. It is important to notice that these ribbon-like crystals are organized in parallel arrays that
ultimately dictate the highly-ordered arrangement of bundles of enamel crystals (i.e., enamel rods)
found in mature enamel. In developing enamel [42,49], the c-axes (long axes) of these crystals are co-
aligned and generally run in parallel to the overall direction of the enamel rod. Subsequently, the
enamel matrix matures into a hypermineralized inorganic tissue (about 96% inorganic content).
Specialized proteins, amelogenin, ameloblastin, and enamelin, constitute the mineralizing enamel
matrix. During the maturation stage, coincident with the almost complete removal of enamel proteins
by resident proteases, these mineral ribbons grow rapidly in thickness and width, resulting in
a mineralized tissue that is >95% mineral (by weight), with only 1–2% remaining protein (the missing
percentage is mostly water), in a way that maintains the structural organization of the enamel crystals
established during the secretory stage [50]. These findings suggest a functional relationship between
organic matrix removal and subsequent mineral growth. The transient nature of the enamel matrix is
unique and distinguishes enamel formation from other systems in biomineralization.
Similar to bone, enamel possesses a complex architecture, which can be broken into several hier-
archical levels from the nanoscale to the macroscale [51] (Fig. 3). On the nanoscale, the protein–protein
and protein–mineral interactions in the presence of supersaturated calcium phosphate solutions create
a highly organized array of HA crystallites that grow preferentially along the c-axis [52]. The sizes of
these crystallites depend on the stage of the mineralization. The crystallites grow primarily in length
during the secretory stage and continue to grow in width and thickness during the maturation stage.
The assembly of amelogenin has been shown to be crucial for the proper development of enamel
crystallites [53,54]. Disruption of the assembly alters the formation process on the nanoscale, subse-
quently affecting larger length scales and giving rise to a diseased or malformed enamel phenotype. On
the mesoscale level, there are three main structural components: the rod, the interrod and the
aprismatic enamel. The main component of enamel on the mesoscale includes rods, which are bundles
of aligned crystallites that are “woven” into intricate architectures that are approximately 3–5 mm in
diameter [55]. The second structural component of the enamel matrix is the interrod (or inter-
prismatic) enamel, which surrounds and packs between the rods. The difference between the rod and
the interrod is the orientation of HA crystals; the rod contains aligned crystallites, whereas the mineral
in the interrod is less ordered. These structures coalesce to form the tough tissue of enamel, which can
withstand high forces and resist damage by crack deflection. The third structure, aprismatic enamel,
refers to the structures containing HA crystals that show no mesoscale or macroscale alignment. The
macroscale architecture includes specific zones of enamel that have unique characteristics, which
contribute to the whole tissue. The enamel adjacent to the dentin–enamel junction (DEJ) exhibits
a gradual transition from dentin to enamel. Aprismatic regions of enamel have been proposed to be
primitive areas of the tooth serving as a toughening mechanism due to their flexible nature [56].
Fig. 3. Hierarchical architecture of mammalian enamel. Enamel (E) is the outermost layer at the crown of the tooth and resides
above the dentin (D). The pulp (P) contains nerves and blood vessels, while the cementum (C) is the outermost layer of mineralized
tissue surrounding the root of the tooth allowing the tooth to be anchored to the jawbone through the periodontal ligament (PDL).
The bulk image depicts the E organ, the transition across the D–E junction, and the D below. On the mesoscale level, prismatic E
consisting of weaving of rods (or prisms) that range from 3 to 5 mm in diameter can be visualized. Upon further magnification, the
micrometer scale shows the composition of a single rod. The nanometer scale reveals a highly organized array of individual HA
crystallites (approximately 30 nm thick, 60 nmwide, and several millimeters in length), which are preferentially aligned along the c-
axis. Reprinted with permission from Ref. [58]. Copyright 2008 Cambridge University Press.
Several authors have identified these aprismatic areas to be located adjacent to the DEJ and at the
incisal surface of both deciduous and permanent human enamel [57].
Over the last 40 years, a remarkable effort has been made to elucidate the mechanism by which
enamel matrix proteins regulate the formation and organization of the enamel tissue. Although
significant advances have clearly been made during this time, the complete mechanism of enamel
formation is still unknown. Such progress has led investigators to suggest that the predominant enamel
matrix protein, amelogenin, self-assembles to form organized supramolecular structures that facilitate
crystal organization [59,60], prior to its subsequent removal during tissue maturation. This suggestion
was based, in part, on the detection of chains of nanometer-sized spheres by using TEM observations of
both dehydrated resin-embedded [61] and non-dehydrated freeze-fractured sections of forming dental
enamel [62]. It was further suggested that such aggregates, alone or in combination with other
proteins, facilitate the nucleation and organization of mineral phases [41]. Although this conceptual-
ization is very interesting, especially given its similarity to mineralization mechanisms in collagen-
based tissues, the precise mechanism by which enamel matrix proteins regulate such processes is
not well-understood. Nevertheless, evidences suggest that both protein–protein interactions and
protein–mineral interactions (in particular amelogenin proteins) play crucial roles in the regulation of
enamel mineral formation and organization.
To better comprehend the enamel formation in addition to the protein–mineral interactions, the
role of fluoride has been investigated. In the last five decades, fluoride has been used for the treat-
ment of dental erosion and caries prevention through different modalities [63]. In addition, the effect
of fluoride on the nanostructure of remineralized apatite has been well documented [64]. However,
despite its use in humans as remineralizing agent, its benefits are not still clear due to the fact that
the optimal dose of fluoride resulting in a positive effect on enamel remineralization with minimum
risk of toxicity has not been well documented. In this respect several recent studies have demon-
strated the excellent properties as remineralizing agent of the apatite as such (especially nanosized
apatite) [65–67].
Several works have suggested that enamel crystal growth comprises two events: the two-
dimensional growth of an OCP-like precursor in a narrow outermost zone adjacent to the amelo-
blasts and the subsequent overgrowth of apatite units on the template under discrete fluid environ-
ment in the underlying region distant from the cell layer. In this way, the presence of 0.1–2 mg/l
fluoride in the mineralizing solution is known to promote hydrolysis of OCP to apatite [68,69] and
fluoride can accelerate epitaxial growth of apatite crystals on the OCP precursor, changing the crystal
morphology. It has also been shown that at 0.1–1 ppm fluoride the ribbon-like OCP changes to an
interlayered structure whereas at 2 mg/l needle-shaped apatite crystals were produced [68,70].
Fluoride was hypothesized to reduce growth of (100) face of OCP and to cause needle-like crystal
structure formation. Recently Fan et al. have demonstrated that 1 mg/l fluoride was effective in altering
the crystal nanostructure from porous plate-like OCP to a 20–50 nm diameter needle-like array of
fluoridated apatite nanocrystals [71]. The biomimetic mineralization system used in this work
(supersaturated calcification solutions were used to initiate the growth of calcium phosphate crystals
on the etched enamel surfaces), at best of our knowledge, is a first step toward developing a clinically-
applicable means of forming an enamel-mimicking mineralized layer, under minimal fluoride expo-
sure, on eroded or damaged tooth enamel. However, direct evidence of the effect of F ion on the
morphology and nanostructure of crystal growth at a nanoscale level on an enamel surface has not
been reported yet.
3. Crystallization of apatites with tailored surface properties
3.1. Precipitation of amorphous calcium phosphate (ACP)
Amorphous calcium phosphate is thermodynamically unstable which usually spontaneously
transforms into crystalline calcium phosphate, mainly apatite. However, this instability and the easy
transformation to crystalline phases are of a great biological relevance. Actually, ACP has been
considered as a precursor phase of bone mineral in vertebrates which play a key role in intrafibrillar
mineralization of collagen fibrils [72]. Recently, Weiner et al. reported that ACP is amajor component of
the first-formedmineral phase of bone [73]. Additionally, Nancollas et al. on the basis of thework of Hu
et al. [23] have suggested that citrate can strongly influence early ACP formation [74]. They proposed
that at an early stage of nucleation in the presence of citrate, only some citrate molecules can partly
bind with the cluster surface, inhibiting their further aggregation, and thus increasing the induction
time [74]. In the later nucleation stage, the ACP clusters aggregation can be promoted by the presence
of non-collagenous protein. Although some citratemolecules can interact with the amorphous clusters,
the binding area density is low, owing to the continuing mismatch between the spacing of the terminal
carboxylate groups in citrate and the structural parameter of the amorphous clusters. In fact, the
interaction of the citrate molecules and ACP clusters can slow down but not inhibit the transformation
process to crystalline apatite. On the other hand, the area density of citrate binding on the crystal
surfaces increases because the spacing of carboxylate groups in citrate matches that of calcium ions of
the ð1010Þ planes in apatite [23]. Thus, the crystal growth is inhibited along the [100] direction
(reducing so the thickness of the nanoparticle) but it grows along the c-axis. Hence, it is clear that
citrate and non-collagenous proteins play a key role on the tailoring of not only the transition fromACP
to apatite but also the thickness and crystal orientation of apatite on the collagen fibrils.
3.2. Crystallization methods of apatites
Numerous methods have been used for the synthesis of apatite crystals. They can be classified into
the following categories: wet chemical precipitation [75–77], sol–gel synthesis [78–80], co-
precipitation [24,81], hydrothermal synthesis [82–84], rapid or continuous precipitation from solu-
tion [85], mechanochemical synthesis [86], microwave processing [87–90], vapor diffusion [91–93],
silica gel template [94], emulsion-based syntheses [95], electrospraying [96], electrospinning [97], flux
cooling [98] and other methodologies producing (nano)crystals of various shapes and sizes [99,100].
Dorozhkin [5] has recently produced a review of thosemethods producing nanocrystalline apatites and
has underlined that the interest for nanocrystalline apatites was quite recent. In fact the systematic
investigation on these materials did not commence until 1994.
Using as criteria the control of apatite structure andmorphology, the crystallizationmethods can be
divided into high and low temperature approaches. The synthesis at high temperature usually involves
the homogenization of precursor compounds, such as Ca3(PO4)2 and Ca(OH)2, and their annealing at
about 1000 !C. The advantage is the possibility to set the final stoichiometry of the product, whereas
the main downsides are the long processing times and high annealing temperatures. In general, when
using this method the Ca/P ratio is a crucial parameter; in fact, if the initial molar ratio of Ca/P is not
well set to 1.67, extraneous phases could appear such as a- or b-TCP at values lower than the stoi-
chiometric Ca/P ratio and typically CaO at higher values. The a-TCP phase is normally formed at
temperatures around 1200 !C whereas the b-TCP phase is formed at lower temperatures, up to 900 !C.
In addition to the high levels of energy consumption, another major downside of high temperature
methods is the difficulty to produce uniform and nanosized crystals [101].
The synthetic methods at low temperature involving precipitation from solution offer the advan-
tage that they can produce nanosized crystals, but a disadvantagemay be in some cases the presence of
transient andmetastable phases in the final product. The samples produced by these methods are then
generally nonstoichiometric and poorly crystallized. Indeed, the analyses carried out on several
samples allow to assess that they have the typical features of biological apatites such as a poor degree
of crystallinity, the existence of ionic surface disorder (non-apatitic surface layer) and surface
compositions different from the bulk in nanocrystals, which consists on the presence of non-apatitic
anionic and cationic chemical environments and sometimes labile carbonates.
As explained previously, biological apatites are known for their high content of defects, caused in
part by a relatively large percentage of ionic substituents, all of which affect the lattice parameters,
crystal morphology, crystallinity, solubility, and the thermal stability of the material. Biological apatite
crystal surface is thus rarely smooth, which is also linked to biological significance. The exceptional
roughness, comprising surface irregularities in the order of size of single unit cells, hypothetically
corresponds to the tendencies to increase protein binding in the process of biomineralization. More-
over, recent studies have shown that rough surfaces improve biocompatibility of the material and have
a positive effect on inflammatory reactions [102]. For this reason, evolution in the preparation
techniques has led to methods for obtaining apatite in nanosized forms, mimicking those naturally
occurring in bone. Structure is also important for biomimetism, as the mineral component of bone has
well-defined features in relation to bone tissue function and age [103]. In this respect, the possibility to
turn quite smoothly the bulk structure from highly to poorly crystalline by changing preparation
conditions, such as temperature, pH, presence of anionic and/or cationic substituents, or else nucle-
ation on a substrate such as collagen fibers, is well-known [104].
To investigate the effect of temperature on nanosized apatite, Sakhno et al. compared two types of
samples synthesized at 40 !C and 95 !C [105]. The apatite synthesized at low temperature displayed
platelet-like morphology and are constituted by a crystalline core coated by an amorphous surface
layer 1–2 nm thick (Fig. 4). By increasing the preparation temperature, the platelet morphology was
retained but apatite nanoparticles exhibited a higher degree of crystallinity (evaluated by X-ray
diffraction techniques). HRTEM observations revealed that, in this case, the crystalline order was
extended up to the particles surfaces, exhibiting the planes (010), (100), and (001). IR spectroscopy was
used to investigate the surface hydration of both materials, in terms of adsorbed H2O molecules and
surface hydroxyl groups, as well as the Lewis acidity of surface cations, by removing water and
adsorbing CO [106]. For both features, strong similarities between amorphous and crystalline surfaces
were found. However, interestingly the apatite synthesized at 95 !C with crystalline surfaces appeared
able to physisorb multilayers of water in a larger extent than less crystallized samples.
Nowadays, the interest for nanocrystalline apatites is still rising thanks to their new applications in
biomedicine requiring control of shape and size distribution as well as tailored surface properties (see
in particular Section 4). Although there are numerous methods to produce nanocrystalline apatites in
a controlled manner, the preparation of actually biomimetic and surface- or bulk-tailored nanocrystals
is still a scientific and technological challenge. In this sense variations of already established meth-
odologies such as the method based on precipitation from metastable Ca/citrate/phosphate solutions
[24] or new methodologies, not yet explored, are being investigated to get these materials.
Delgado-López et al. have prepared citrate-functionalized carbonate-apatite nanoparticles with
mean lengths ranging from 20 to 100 nm by a thermal-decomplexing batch method [107]. This
crystallization method consists on the thermal decomplexing of metastable calcium/citrate/phos-
phate/carbonate solutions that produces a gradual and homogeneous release of Ca2þ ions in the
solution producing, thus the precipitation of nanocrystalline apatites. They also studied the effect of the
maturation time and the presence of sodium carbonate in the solution on the physico-chemical and
structural properties of the nanoparticles. They found these two experimental conditions play an
important role in tailoring both the physicochemical and the morphological properties of nano-
crystalline apatites such as size, composition, and crystallinity. At short precipitation time, poorly
crystalline 100 nm-mean length apatites with low carbonation degree (1.5% w/w, mainly as B
substitution) and high citrate content (5.9% w/w)were precipitated. Interestingly, this citrate content is
close to that recentlymeasured on bone apatite [23]. When increasing the precipitation time up to 96 h
the mean length and the citrate content progressively decrease and at the same time the nanoparticles
Fig. 4. (Left) High resolution TEM image of a portion of apatite synthesized at 40 !C (main panel, left), related FT and zoomed view of
two border regions (right panels). Original magnification: 800k#. (Right) High resolution TEM image of a portion of apatite
synthesized at 95 !C (main panels A and B), related FT (right, bottom). Panels A, A0: zoomed view of two enframed border regions in
panel A. Original magnification: 800k#. Reprinted with permission from Ref. [105]. Copyright 2010 American Chemical Society.
become more crystalline. The presence of carbonate in the solution favors its incorporation in the
crystal lattice up to 3.1% (both, in A and B positions) giving rise also to shorter and more isometric
nanoparticles. Hence, this work provides new insights on the role of citrate to tailor the apatite
nanocrystal size. The nanoparticles were composed of a well-ordered carbonate-substituted apatitic
core embedded in a non-apatitic hydrated layer containing citrate ions. This layer progressively
transforms into more stable apatite domain upon maturation in aqueous media. Moreover, the
nanoparticles prepared by this method displayed excellent compatibility properties in cell biology
systems, since they were not cytotoxic to a mouse carcinoma cell line, when added until a final
concentration of 100 mg mL'1.
One of the most interesting system to produce apatite nanocrystals at low temperature is the
mechanochemical–hydrothermal (M–H) method. The main advantages of this kind of synthesis of
ceramic powders are simplicity and low cost since conventional milling equipment can be used. The
(M–H) technique is located at the intersection of hydrothermal and mechanochemical processing.
Mechanochemical powder synthesis is a solid-state synthesis method that uses the perturbation of
surface-bonded species by pressure to enhance thermodynamic and kinetic reactions between solids.
Pressure can be applied at room temperature bymilling equipment ranging from low-energy ball mills
to high-energy stirred mills. M–H synthesis (sometimes called “wet” mechanochemical), takes
advantage of the presence of an aqueous solution in the system. The aqueous solution actively
participates in the mechanochemical reaction by acceleration of dissolution, diffusion, adsorption,
reaction rate, and crystallization. The mechano-chemical activation of slurries can generate local zones
of high temperatures (up to 700 !C) and high pressures due to friction effects and adiabatic heating of
gas bubbles, while the overall temperature is close to the room temperature. The M–H technique
produces comparable amounts of calcium phosphates powder as the hydrothermal processing, but it
requires lower temperature than the hydrothermal process. Shuk et al. crystallized for the first time
agglomerates of nanocrystalline apatite (about 20 nm in size) from heterogeneous reaction between
Ca(OH)2 powders and (NH4)2HPO4 solutions via the M–H route [108]. More recently, several authors
improved the basic knowledge about this method and investigated the effects of pH, surfactant and
polymer on the features of synthesized apatite nanocrystals [109–111]. Moreover the possibility to
produce substituted apatites with carbonate, magnesium and fluoride by M–H technique was also
studied [112,113,114].
Recently, Iafisco et al. reported a newmethodology, based on the vapor diffusion sitting dropmicro-
method, to precipitate carbonate-substituted apatite nanoparticles [91,92] (Fig. 5a). The method was
developed by using an innovative device called the “crystallization mushroom” [115,116], which offers
the advantage of a reduced consumption of reagents, since the volume of micro-droplets is around
40 mL and the high reproducibility due to the possibility of running 12 batches for each experiment.
Therefore, this setup is suitable to evaluate interactions and/or the co-crystallization of apatite with
small amounts of proteins, polymers, or drugs for studies in the fields of biomineralization and
biomaterials. By using this methodology it has been found that mixtures containing 50 mM Ca(CH3-
COO)2 and 30 mM (NH4)2HPO4 in micro-droplets and 3 mL of a 40 mM NH4HCO3 solution in the gas
generation chamber were the optimal concentrations to precipitate carbonate-apatite nanocrystals
after 7 days of reaction. The nanocrystals were produced by solvent mediated phase transformation of
octacalcium phosphate (OCP) to apatite, with OCP most probably acting as a temporal template for the
heterogeneous nucleation of apatite nuclei. The obtained crystals displayed nanometric dimensions,
carbonate ions in the crystal lattice, plate-like morphology, and low crystallinity degree, closely
resembling the inorganic phase of “young bones”. Nassif et al. [93] also precipitated carbonate-apatite
by the vapor diffusion method. They used CaCl2–NaH2PO4 mixed solutions in the volume range of
milliliters (macro-method) and either a NH4OH and NaHCO3 solution or solid (NH4)2CO3 to generate
the gas phase, which led respectively to the precipitation of B- or A-type carbonate-apatite phases.
They concluded that the best similarity between synthetic and natural apatitewas obtained by using an
aqueous carbonate precursor. This result agrees with those obtained by Iafisco et al. [92].
The analysis of the existing literature reveals that optimal routes to synthesize nanocrystalline
apatites analogous to biogenic apatites are the low temperature methods, and also that in order to
optimize their specific biomedical applications the particle dimensions, porosity, morphology and
surface properties are major physical-chemical features that should be tailored. An approach consists
in using methods of precipitation in the presence of small amounts of additives [117,118]. The inter-
actions between the growing inorganic particles and certain additives are governed mainly by elec-
trostatic forces which can be tuned by controlling the zeta potential of colloidal particles. These forces
are crucial for setting the optimal conditions for the growth of nanocrystals in different sizes and
morphologies. Elongated apatite particles were for example obtained in the presence of poly(L-lysine),
whereas in the presence of more charged poly(L-glutamic acid), small nanocrystals were precipitated
[119]. These additives thus act as inhibitors for the crystallization of apatitic crystals. A similar inhib-
iting effect was found for other molecules such as dimethyl acetamide [120], polyvinyl alcohol [121]
and several other (bio)polymers [122], among others (more details on this matter are also given on
Section 4).
Among the additives, aminoacids are biological molecules of particular interest since they are the
smallest molecular components of proteins. The effects of hydroxyproline, tyrosine, serine, glycine,
cysteine, cystine, glutamine and lysine on apatite crystallization have been studied by the “Chemo-stat
method” by Koutsopoulos et al. [123–125]. Diverse inhibiting activities were then observed as
a function of the different aminoacid side groups. All these studies have utilized biomolecules as simple
growth inhibitors of HA crystallization, rather than considering their use as a strategy to fine-tune the
bioactivity of the apatite crystals. In fact, considering that the presence of proteins in biological
materials is intrinsic to the bioactivity of apatite, aminoacids can be considered as agents that can
increase the bioactivity of synthetic apatites. This idea was first developed by Gonzalez-McQuire et al.
[126], who obtained, by hydrothermal crystallization, stable aqueous colloids of positively charged
aminoacid-functionalized apatite nanorods of less than 80 nm in length and ca. 5 nm inwidth. Greatly
elongated apatite nanorods, of ca. 150 # 3.5 nm, were prepared with aspartic acid. The above work
inspired further investigations into the nature and stability of the interaction of a series of aminoacids
with apatite [127–129]. Together with the “Chemo-stat method”, these studies also suggested that
crystallization kinetics is affected through the inhibition by aminoacids of the active growth sites of the
apatite crystals surface. These sites could be constituted by surface calcium or phosphate ions (often
protonated), and less probably by a few exposed hydroxyl groups. These experiments suggest that
there may be a complex multi-site adsorption process, that may be “switched” on or off by changing
the pH, since it affects the formation of different surface complexes between COO' and Ca2þ at
different sites.
Biomimetic nonstoichiometric apatite nanocrystals with aminoacid (alanine, arginine and aspartic
acid) surface functionalities and different morphologies (depending on the aminoacid used as co-
reagent during the synthesis) have been obtained by Palazzo et al. [130]. A self-assembly mecha-
nism could be supposed, considering that the crystals domain size appeared slightly decreased by the
aminoacid presence, while the nanocrystal grows unidirectionally. Zeta potential measurements then
showed that the aminoacid-functionalized apatite surface charge is inverted, being shifted toward
neutrality with respect to that of the apatite (Table 2).
Fig. 5. TEM images of carbonate-hydroxyapatite crystals grown by the sitting-drop vapor diffusion (a) and by the batch precipitation
from metastable Ca/citrate/phosphate solutions. (b) Scale bars are 200 nm.
This chemical surface modification is found to dramatically affect the biological properties of the
apatites, and should thus offer the potential for the nanocrystals to be used as carriers of bioactive
molecules linked to the aminoacidic residue. Aminoacid is the anchoring agent between apatite and
bioactive molecules, dramatically affecting the adsorption and release kinetics. It was found that, while
the introduction of the aminoacids during the apatite nanocrystal synthesis induces a modification in
the primary crystallite domains along the c direction and along its transverse directions, only polar
aminoacids induce a morphological and dimensional variation in the apatite nanocrystals. Considering
that the crystal domains sizes appear slightly decreased by the presence of the aminoacid while the
nanocrystal grows unidirectionally, a self-assembly mechanism of nanocrystal formation can be
supposed.
As was said earlier, zeta potential measurements showed that the surface charge of aminoacid-
functionalized apatite was inverted compared to the unfunctionalized apatite shifting toward
neutrality. The role of the lateral residue in the binding mechanisms, involving either the carboxylate
group (in the case of alanine and aspartic acid) or the amino lateral group in the case of arginine, has
been underlined.
Although each of the reported approaches to produce nanosized apatites has both a scientific and
a practical relevance, only little attention has been dedicated to-date to the physico-chemical aspects
involved in the careful control of the particle size distribution and particle shape. Indeed, in the case of
particle size distribution, most of the reported ways to synthesize nanosized apatites really produce
a mixture of particles with a wide size distribution from tens to hundreds of nanometers. In fact, the
control of nanoparticle shape is another problem for thesemethods, which commonly result in pin-like
or irregular particles. The size-controlled synthesis of materials can be achieved by using limited
reaction spaces; namely microemulsions [131], micelles [132] and reverse micelles [133] have been
successfully applied to the synthesis of nanosized apatites. In some cases, special polymers can be used
as spatial reaction vessels for their fabrication. Mann et al. pioneered the use of organized molecular
systems such as microemulsions to mimic the basic biomineralisation process in which mineral phase
nucleation and growth is coupled with self-organized construction [134]. The micrometer-sized
droplets of supersaturated solution stabilized in oil by surfactant molecules consist of microreactors
where the reactions take place, and the nucleation and growth of mineral phase occurs specially at the
surfactant headgroups segregated at the oil–water interface. Such systems can be used for the
synthesis of apatitic nanocrystals, their growth (from about 10 nm thickness), occurred in a preferential
direction oriented on the organized molecular support [131,135].
3.3. Crystallization mechanisms of nanocrystalline apatites
When using low temperature synthetic methods to produce nanocrystalline apatites, a disadvan-
tage in some cases is the presence of transient phases in the final precipitates. To explain the possible
presence of these extraneous phases the already published solubility phase diagrams can be consid-
ered. The one published in 1992 by Johnsson and Nancollas [136] was performed at 37 !C and ionic
strength 0.1 M. According to this diagram, the calcium phosphates phases decrease their solubilities
with the increase of pH. At pH above 4.0 HA is the most stable phase followed by TCP and OCP, whereas
at pH values lower than 4.0 the DCPD phase is more stable than HA. The position of the curves will
changewith the change in temperature and the ionic strength. On the other hand, the one published in
2009 [H.B. Pan and B.W. Darvell, Crystal Growth Des, 2009, 9, 2, 639–645] considers that DCPD is not
the most stable phase below pH w4.2, since calcium-deficient HA is less soluble. The
Table 2
Zeta potential measurements for nonstoichiometric apatite synthesized in the absence of aminoacids and aminoacid-
functionalized nonstoichiometric apatite nanocrystals.
pH of suspensions Zeta potential (mV)
Not-stoichiometric apatite 7.5 '21.2 ( 1.4
Alanine-apatite 7.8 '5.8 ( 1.5
Aspartic acid-apatite 7.6 '6.9 ( 1.2
Arginine-apatite 7.6 '4.1 ( 1.0
misunderstanding arises from themetastability of DCPD, which nucleates muchmore easily than HA at
low pH. This fact highlights the importance of kinetic factors when defining the pH domains in which
a certain CaP phase can be formed in a precipitation experiment.
Thus, parameters such as pH, ionic strength, temperature, aging time, concentration and type of
additives, Ca/P molar ratios and supersaturation have to be considered for the control of the formation
of apatites [137]. The pH significantly affects the precipitation of HA because of its influence on the
amount of free OH' groups and on the balance of phosphate species. A shift to low pHwill decrease the
saturation level by diminishing the concentration of free OH' groups and shifting the balance of
phosphate species from PO4
3' to HPO4
2' to H2PO4
' to H3PO4. Hence, at low pH, the phosphate groups
are protonated, and the precipitation is less favored. Moreover, the pH can shift the surface charge of
the interacting particles by changing the distribution of proton and hydroxyl groups at the interface.
Although H3O
þ and OH' are usually considered as charge-determining ions in the case of HA particles,
other ions can adjust the surface charge, and in particular, in calcium-containing solutions, Ca2þ ions
may bind to the negatively-charged HA surface at pH > IEP (isoelectric point), leaving the surface
neutral rather than negative. The opposite effect can take place in phosphate-rich solutions when
binding of HPO4
2' species at pH < IEP may result in a negatively-charged HA particle surface rather
than the positive.
One of the best accepted models for the crystallization of HA is the Ostwald–Lussac model which
predicts the highest nucleation rate for the least stable phase for which the supersaturation limit is
exceeded under given conditions. This model implies that an amorphous calcium phosphate (ACP) will
be the first phase to precipitate, followed by the solid state transformation to OCP and then to HA.
Ca(OH)2 or TCP may be secondary phases depending on the exact stoichiometric ratio between the
precursor Ca2þ and phosphate ions in the solution. However, the exact chemical pathways, the
transformation mechanism (dissolution/recrystallization or bulk rearrangement of ions within the
prime crystal lattice), the transient compounds, and time frames for the nucleation and growth of each
one of the phases are still subject to uncertainty.
The most important parameter used to describe the precipitation of HA (at a given temperature) is
the supersaturation ratio S ¼ Q/Ksp, where Q is the product of ionic activities of precursor ions in the
solution for the given stoichiometry (for half a unit cell of HA, Q ¼ ½Ca2þ+5½PO4
3'+3½OH'+), and where
Ksp is the product of ionic activities for the given compound at the saturation level (solubility product).
In view of the continuous transfer of the matter across the solid/liquid interface in both directions, Ksp
could be also defined as the product of activities of dissolved ions of a solid substance in equilibrium
between the dissolved ions precipitating and the precipitated ions dissolving. Ostwald–Lussac rule
postulates that the most soluble phase (i.e., the least stable) for which S > 1 is the first to precipitate,
which will be successively followed by precipitation of less soluble phases. The reason for this is that
the thermodynamic barrier between the state occupied by dissolved ionic species and the solid phase
will be the lowest for the thermodynamically most unstable phase (Fig. 6) [138,139].
An important contributor to this effect is the surface/interfacial energy, that is, the work required to
increase the surface area of a substance by one area unit, which is the obstacle that must be overcome
when forming a solid phase. An amorphous phase is less ordered than a crystalline phase and it has
a lower interfacial energy (particularly if it is hydrated, it is most similar in chemistry to the
surrounding aqueous environment) which implies that it tends to be the first to precipitate prior to
subsequently transforming into a more stable, crystalline modification. In the case of the precipitation
of calcium phosphates, this means that HA could be the last phase to form. The initial precipitation of
ACP is normally followed by nucleation of OCP at a certain stage. However, only the phases with S > 1
are involved in this successive precipitation. Those for which S < 1 are assumed not to be precipitated
at any stage of this process, and their appearance may only be transitory during phase transitions that
involve rearrangements of ions in the solid state. This kinetic rulewas empirically observed, although it
can be nowadays supported by theoretical arguments. In one such calculation [140], it was shown that
in simulated body fluid (SBF), whose S normalized per growth unit (n ¼ 9 for HA) equals 19.5 with
respect to HA, the nucleation rate of OCP is higher than the one for HA, implying that OCP would be the
preceding crystalline phase to form.
Intermediate phases are thus expected to play a crucial role in defining the morphology, the
interfacial properties and the growth mechanism of the HA. Hence, the first phase that should form
upon precipitation of calcium phosphates is an amorphous phase. The particles initially formed would
be agglomerates of amorphous calcium phosphates units. Only in the following stage, the trans-
formation of this phase into apatite and any other phase with S > 1 under the given conditions would
take place. Under the conditions that resemble the physiological ones (pH about 7.4 and T ¼ 37 !C), the
precipitated phases change over aging time (OCP is generally accepted to be the transient phase in
physiological conditions and at pH< 9, whereas themechanism at higher pH is not clearly defined yet).
The solubility isotherms for brushite (DCPD) and OCP at room temperature and for Ca/P molar ratio of
1.16 (resembling the Ca/P ratio within the initially precipitated amorphous phase) interconnect at pH
6.7 (above this value OCP is amore stable phase and the trend is inverted at lower pH). This implies that
according to Ostwald–Lussac rule, the transformation of the amorphous phase to apatite should follow
the OCP to DCPD to apatite route at pH < 6.7, and the DCPD to OCP to apatite route at pH > 6.7 [141].
The formation mechanisms of HA in pure solutions have been deeply investigated in the last
years. An aggregation model of roughly spherical units of composition Ca9(PO4)6 called “Posner’s
clusters” (PC) was proposed in the 60’s to explain the formation of HA via an amorphous precursor,
when working in neutral to basic conditions. The chemical analysis of the precursor amorphous
phase indicated to be a hydrated calcium phosphate (Ca3(PO4)2.xH2O) with a Ca/P ratio 1.50, con-
sisting of close-packed Posner’s clusters to form larger spherical particles with water in the inter-
stices [142–144].
After these pioneering works several researchers found evidences that strongly support an
aggregation mechanism to explain HA formation. The mechanism proposed by Melikhov [145] can be
divided into the following steps: (i) homogeneous nucleation of ACP; (ii) aggregation of primary ACP
particles into typically spherical units; (iii) aggregation of spheres into chain-like structures; (iv)
growth of these structures; (v) secondary precipitation and phase transformation. The initially
precipitated particles of the amorphous phase were observed to be round-shaped with 20–30 nm in
size (although they can reach 120 nm in size) [145], but composed of smaller particles of 4 nm in size on
average. It was also observed that an increase in the ripening time implied aggregation of spherical
singlets and formation of needle-shaped calcium phosphates particles of about 20 nm in length [146].
Rodríguez Clemente et al. [147] proposed a model of nucleation-directed aggregation–agglomer-
ation-growth mechanism to explain the formation HA with micrometer size. The mechanism is based
on empirical results of the precipitation of HA in batch and continuous process at 85 !C as well as
Fig. 6. Crystallization pathways under thermodynamic and kinetic control. Whether a system follows a one-step route to the final
mineral phase (pathway A) or proceeds by sequential precipitation (pathway B), depends on the free energy of activation (DG)
associated with nucleation (n), growth (g), and phase transformation (t). Amorphous phases are common under kinetic conditions.
Reprinted with permission from Ref. [138]. Copyright 2003 John Wiley & Sons, Inc.
HRTEM characterizations of the microparticles and the inconsistency of the classical nucleation-
growth-agglomeration mechanism to explain the crystal size distributions of the HA obtained in
their precipitation experiments. According to this model, the formation mechanism of particles starts
with a nucleation episode, followed by the aggregation of supercritical nuclei ruled by surface energy
excess, which counterbalance the repulsive forces between particles. The aggregates agglomerate,
forming solid bridges, and these agglomerates continue to grow as distinct particles due to repulsive
forces. This model allows to explain, for example, the precipitation of nanocrystalline apatites from
complexed Ca–citrate–phosphate solutions. The specific surface area measurements (BET method),
XRD, FTIR and microscopy analyses (TEM and SEM) showed that in the case of precipitation from Ca/
citrate/phosphate using sodium salts as reagents, the particle formationmechanism involves the initial
precipitation of Na3cit.4H2O, which acts as a temporary template. The heterogeneous nucleation of
nanosized apatite in this system is interpreted in terms of surface free energy excess minimization by
the interaction of the supercritical nuclei with this template. Afterwards, these supercritical nuclei
grow to their final nanometer size, the template–particle interaction prevents the formation of apatite
aggregates and, thus, allows the formation of primary nanosized particles at the time that the template
dissolves. When using potassium salts or EDTA instead of sodium citrate as complexing agent, there
was not an initial precipitation of a template and then apatite particles grew to final submicrometer or
micrometer sizes. It is interesting to note that precipitation of a metastable phasewhich later dissolves,
or the coprecipitation of both phases simultaneously, offers a unique way to obtain nanosized solid
phases in natural and artificial crystallization from solution, which would otherwise be impossible to
obtain due to surface energy excess.
Very recently the group of Sommerdijk revealed that ACP formation proceed via aggregation of
prenucleation clusters before the development of oriented apatite crystals. High-resolution cryoTEM
demonstrated that at 25 !C the simulated body fluid (SBF) solution that they employed contained
isolated nanometer-sized prenucleation clusters. After increasing the temperature to 37 !C these
clusters were present partially as individual entities or as small aggregates, but mainly as loosely
aggregated networks within the bulk solution [148]. Size analysis of the observed clusters showed an
average diameter of 0.87 nm, in line with previously reported cluster sizes (0.70–1.00) nm [149] and
the theoretical size of Posner’s clusters (0.95 nm) [144].
4. Advances in the characterization of nanocrystalline apatite surface – study of surface
interactions
4.1. Introductive remarks on the need for precise and complete characterization data
Generally surfaces are difficult to characterize since they are easily contaminated and often exhibit
great ion mobility, reactivity or metastability. This holds especially with calcium phosphate-based
biomaterials. Therefore, great care has to be dedicated to the characterization of such systems.
Indeed, significant departure from stoichiometry can be evidenced and is bound to have a noticeable
impact on most of the sample properties. The full description of titration methods is not the object of
this paper and has been addressed elsewhere [4], however we will summarize here the main aspects.
The determination of calcium, total phosphate and carbonate ions can be performed nowadayswith
good accuracy using various methods. All these methods are based on the dissolution of the apatitic
powder in acidic solution before the analysis (calcium and orthophosphate ions determination) or
during the analysis (carbonate ions). Calcium contents can be assessed chemically by way of com-
plexometry with EDTA [150] and orthophosphate ions contents ðPO4
3' and HPO4
2'Þ using a yellow
phosphovanadomolybdenum complex formed in acidic conditions [150]. The Ca/P mole ratio of apatite
compounds is then the result of these analyses, and this ratio is often used to compare samples.
Relative uncertainties on calcium and phosphorus concentrations obtained this way are of the order of
0.5%. Alternative methods as for example ICP or atomic absorption can measure lower ionic concen-
trations than the current chemical methods, but phosphate concentrations are more difficult to asses
on an ICP basis due to possible matrix effects in the presence of other ions in the systems. The titration
of HPO4
2' ions only is, on the contrary, an indirect method exploiting the condensation of HPO4
2' ions
into pyrophosphates P2O7
4' upon heating (e.g. 600 !C, 1 h), since the latter cannot form the yellow
complex [151]; and the HPO4
2' content is then reached by comparisonwith the data obtained without
heating. The relative error is then again of about 0.5%. It shall be noted however that this method
cannot be used to accurately quantify the HPO4
2' content in bone and in synthetic carbonated apatites
due to the presence of carbonate ions which can interfere with the formation of pyrophosphate ions.
The carbonate content of apatites can be determined using a CO2 coulometer that measures the CO2
released during sample dissolution in acidic conditions. It should be added here that the mole ratio Ca/
(P þ C), where C denotes the amount of carbonates, should replace Ca/P for assessing the global (non)
stoichiometry of carbonated apatite samples.
Thematerials should not only be investigated in their dry state (i.e. as produced), but also, insofar as
possible, in humid conditions close to the conditions of use. In this last case, the in-situ characterization
of the biomaterial/living system interface is then an important complement for drawing an accurate
picture of the situation of the biomaterial and its surface after implantation.
Table 3 summarizes the main characterization techniques suitable for a detailed physico-chemical
characterization of calcium phosphate-based biomaterials, where the techniques particularly suited for
in-situ analyses have been underlined. Spectroscopic techniques (solid state NMR, FTIR and Raman) are
in particular extremely useful for characterizing calcium phosphate systems, possibly carbonated, since
the constitutive phosphate (whether in the form of PO4
3' or HPO4
2' ions), carbonate ðCO3
2'Þ and
hydroxide ions (OH') give very specific signals depending on their local chemical environment(s). For
in-situ analyses, vibrational spectroscopies (FTIR and Raman) are then a good choice for deriving
physicochemical and structural features of synthetic and/or biological nanocrystalline apatites. Indeed,
these techniques are non-invasive, can be used under a broad range of experimental conditions
(temperature, pressure, etc.) and can prove to be surface-sensitive, e.g. with an ATR setup. This latter
setup additionally strongly reduces the strong absorption of IR radiation by the solvent (water) that
allows for the in-situ characterization of the HA interface in contact with biological molecules under
study [152,153]. Information on the behavior of the apatite nanocrystals, especially related to the
nature of adsorbed species, adsorption sites, adsorbate functional groups interacting with the surface
and adsorbate–adsorbate interactions at the apatite interface can for instance be obtained [152,153].
Moreover, the combination of IR and Raman spectroscopies provide a complete overview of the
vibrational behavior of the system under study. In fact, both spectroscopies are among the most useful
techniques for the in-situ characterization of interfaces at a molecular/ionic level in different fields
[154–157].
In the following section, we will summarize the main characteristics of nanocrystalline apatites
(whether of biological nature or for biomimetic synthetic analogs), based on most of the techniques
cited in Table 3, and wewill underline major differences with respect to stoichiometric hydroxyapatite
(HA). The peculiarities of the surface of apatite nanocrystals will also be stressed.
Table 3
Main analytical techniques used for the study of calcium phosphates, especially nanocrystalline apatites, including techniques
used for in-situ interfacial characterization.
Compositional analyses Calcium (Ca2þ) and possibly other cations Complexometry (e.g. with EDTA)
Atomic absorption, ICP, ion
chromatography.
Phosphate ðPO4
3'
; HPO4
2'Þ Colorimetry
Carbonate ðCO3
2'Þ Coulometry
Diffraction X-Ray diffraction (XRD)
Nuclear magnetic resonance Solid-state NMR
Thermal analyses Thermogravimetry (TG)
Differential scanning calorimetry (DSC)
Vibrational spectroscopies Infrared (FTIR) Attenuated total reflection (ATR)
Microspectroscopy
Raman scattering Confocal Raman microscopy
FT-Raman spectroscopy
Microscopies Atomic force microscopy (AFM)
Electronic microscopy Cryo-transmission electron microscopy
4.2. Characterization aspects of nanocrystalline apatites and overview of their peculiar surface features
The peculiar physicochemical and morphological features of nanocrystalline calcium phosphates
have been explored in details in the last years. This has been in particular made possible thanks to
drastic technological evolutions of materials characterization techniques. Additionally, the possibility
to prepare synthetic biomimetic analogs to bone mineral (more or less mature) also enables one to
consider them as excellent bone mineral “models” (replacing the poorly-suited model initially
considered, based on stoichiometric HA). Such models can then be exploited for investigating inter-
actions between bone-like apatite nanocrystals and the components of surrounding fluids (ions,
proteins.) or with drugs (e.g. anti-osteoporotic agents).
Contrarily to stoichiometric HA, biological apatites or their synthetic biomimetic analogs (prepared
under physiological-like conditions of pH and temperature) exhibit a plate-like morphology (with the
large dimension in the c-axis direction). Also, their constitutive crystals are nanosized (with a mean
length of the order of 15–30 nm and an averagewidth of 6–9 nm [158]), as opposed to the much larger,
micron-sized HA crystals. It is also worth mentioning that the crystallinity degree of nanocrystalline
apatites is rather low, as shown by the powder XRD patterns represented in Fig. 7. These compounds
are thus generally referred to as “poorly-crystalline” apatites in the literature. However, it is important
to note that this low degree of crystallinity is perfectly comparable with that of biological apatites from
bone or dentin. This is another criterion for considering synthetic nanocrystalline apatites as good
models for mimicking bone mineral, as opposed to stoichiometric well-crystallized HA (Fig. 7) which is
better suited for mimicking dental enamel.
From a chemical perspective, the composition of nanocrystalline apatites also greatly differs from
that of HA, and this has been an object of controversy during the 20th Century. Taking advantage of the
recent major evolutions in materials science characterization techniques, as mentioned above, it has
however been possible to show [159,160] that bone mineral was composed of nonstoichiometric
single-phased nanocrystalline calcium phosphate apatites (more or less matured as a function of bone
remodeling stage) responding to the global chemical composition:
Ca10Lx ðPO4Þ6Lx ðHPO4 or CO3Þx ðOH or ½ CO3Þ2Lx with 0 £ x £ 2
(except maybe for very immature nanocrystals which may depart from this generic formula). This
formula underlines inparticular the presence of vacancies in both Ca andOH sites, and Legros et al. [161]
reported the following, rather constant formula from the analysis of various cortical bone specimens:
Ca8:3 ðPO4Þ4:3 ðHPO4 or CO3Þ1:7 ðOH or ½ CO3Þ0:3
Fig. 7. XRD pattern for a nanocrystalline biomimetic apatite sample (maturation time in solution: 15 days, RT) and for stoichiometric
HA. Inlet table: Ca/P molar ratio and mean crystallite dimensions (drawn from Scherrer’s formula) for the nanocrystalline apatite
sample shown.
It may however be added that, beside calcium, phosphate, carbonate and hydroxide ions, the
presence of other incorporated ionic substituents as “traces” is also found in biological apatites, such as
sodium or magnesium ions substituting part of Ca2þ ions in the apatitic lattice, or else fluoride ions in
OH apatitic sites [1,2].
It is nevertheless essential to remind that such chemical formulas only refer to the “global”
composition of such nanocrystalline apatite compounds. Indeed, it does not reflect local variations
among the nanocrystals (e.g. within osteons [162]), that are bound to exist due to localized bone
remodeling phenomena for example. Also, it does not take into account the sub-structure within the
individual nanocrystals.
As was previously mentioned, vibrational techniques may be of particular assistance for charac-
terizing phosphate- and/or carbonate-containing systems. FTIR has thus beenwidely applied to obtain
information about structural and/or physico-chemical properties of apatite [157,163,164]. It allows in
particular to identify the chemical environment(s) of phosphate and carbonate ions and, at the same
time, provides structural details of the particles such as crystallinity (to some extent), carbonation type
and carbonation content. Fig. 8 represents a typical FTIR spectrum collected for carbonated nano-
crystalline apatite precipitated by a thermal-decomplexing batch method [24]. The main absorption
band which appears between 1184 and 970 cm'1 is related with the triply degenerated asymmetric
stretching mode (n3) of the O–P–O bonds of the HA phosphate groups. The symmetric stretching mode
(n1) of the same groups appears as a shoulder at 960 cm
'1 whereas the triply degenerated bending
mode (n4) can be distinguished between 630 and 570 cm
'1. The peak position of these vibrational
modes depends on the compositional features of the material [164,165] whereas the bandwidths are
related to both the crystalline domain size and degree of ion ordering into the unit cell; thus, well-
crystallized HA will display well-defined bands whereas a main broad band will be typical for
poorly-crystalline apatites [22,165]. In this context, the full width at half maximum (FWHM) of the
604 cm'1 band (n4) is commonly used to estimate the crystallinity index of the mineral part of bone
[166], although this method should remain associated to XRD crystallographic analyses.
Recent advances in the characterization of apatite nanocrystals by FTIR spectroscopy have however
shown the presence of some chemical environments for phosphate and for carbonate ions (in both
biological apatite compounds and their synthetic biomimetic analogs) that could not be attributed to
regular apatitic ones. For example, detailed analyses of the phosphate groups by FTIR have enabled to
Fig. 8. FTIR spectrum collected for carbonated nanocrystalline apatite precipitated by thermal-decomplexing batch method. The
insets (1) and (2) represent an enlarged view of the typical carbonate spectral region: A-type (marked with A) and B-type (marked
with B) bands.
distinguish (see for example Fig. 9 for the n4(PO4) vibration region) in nanocrystalline apatites the
presence of “additional” bands (as compared to HA) that are not present for regular apatite environ-
ments [167,168]. These chemical environments were then referred to by Rey as “non-apatitic”
environments.
At least two main “non-apatitic” vibrational bands can indeed be visualized for PO4
3' ions (around
617 cm'1) and for non-apatitic HPO4
2' ions (around 535 cm'1), this last assignment to hydrogen
phosphate ions being confirmed by chemical analysis [169]. The presence of such non-apatitic envi-
ronments is thought to be linked to the conditions of formation of apatite nanocrystals (either in vivo or
under physiological-like synthetic protocols).
The presence of non-apatitic ionic environments in biomimetic apatites has also been pointed out
from solid-state NMR. In stoichiometric HA, the 31P chemical shift of all phosphate groups is the same
and leads to a single peak at 2.3–2.9 ppmwith respect to H3PO4 [170–172]. In contrast, in bone or bone-
like apatite, NMR data suggest phosphate environments different from those of regular HA [173–175].
In addition, an asymmetrical broad 31P peak of the main phosphate is often observed [175–177], and
this was related to HPO4
2' ions, which can be evidenced using 2-D 1H4 31P cross-polarization [175].
The analysis of the FTIR n3(PO4) vibration domain is also found to be of interest, in particular in the
case of apatites studied in the wet state (e.g. freshly precipitated, which are not degraded by drying
processes) and where a fine structuration of the n3(PO4) band can be witnessed by FTIR (Fig. 10). In
these conditions, the presence of several fine details can be evidenced in the form of successive
shoulders in the n3(PO4) domain (which is not the case for stoichiometric HA). It is then interesting to
remark that this band structuration resembles to some extent the case of (triclinic) octacalcium
phosphate (OCPt) [4,177], whose structure can be described as a “multi-layered” structure involving
stacked “apatitic” and “hydrated” layers (in a multiple sandwich-like structure) and where the
hydrated layers contain calcium ions as well as all the HPO4
2' content of the OCPt unit cell and several
water molecules [177].
It can nonetheless be noted that some bands present on the spectrum of OCPt (e.g. around 916 and
1195 cm'1) are not detected for nanocrystalline apatites, and thus nanocrystalline apatites should not
be confusively mixed up with octacalcium phosphate. It is also interesting to point out that XRD is also
a way to distinguish these two systems, as the typical (100) XRD peak observed at low 2q angles for
OCPt is not observed for nanocrystalline apatites. Also, it is not possible to incorporate carbonate ions in
the OCPt structure, contrarily to nanocrystalline apatites. Nevertheless, this rather high resemblance
between the FTIR spectral features of OCPt and biomimetic apatites may suggest some degree of
similarity regarding some non-apatitic chemical environments, and these aspects are still under
investigation.
A
b
s
o
rb
a
n
c
e
 (
a
.u
.)
Apatitic PO4
480530580630
Wavenumbers (cm-1)
Apatitic HPO4
Apatitic OH
Non-apatitic PO4
Non-apatitic HPO4
Fig. 9. FTIR spectrum for a nanocrystalline apatite sample, around the n4(PO4) vibrational region.
In a similar way as mentioned above, the FTIR analysis of carbonate ions in apatites can also be
interesting. The amount of carbonate groups associated to the bone mineral nanocrystals (knows as
carbonation degree) can be measured as the area ratio of the n2CO3 (894–862 cm
'1) over n3PO4 (1184–
910 cm'1) regions [166]. Additionally, FTIR data provide not only the amount of carbonate ions present
in the system, but also the carbonate environment(s). Concerning the incorporation of carbonate ions
in the apatite lattice, two “extreme” cases can be distinguished: on the one hand, when carbonate ions
replace tetrahedral PO4 sites (leading to the so-called B-type carbonation), the infrared spectrum
shows bands at ca. 1465, 1413 and 873 cm'1 assignable to the doubly degenerated stretching (n3) and
bending (n2) modes of carbonate groups, respectively [164,165,178]; on the other hand, in A-type
carbonation (where carbonate groups occupy OH positions) the CO3 stretchingmode (n3) shifts to 1546,
1456 cm'1 and the bending mode (n2) appears at 880 cm
'1 [165] (insets in Fig. 8). As for phosphate
chemical environments, in the case of carbonated nanocrystalline apatites an “additional” (non-apa-
titic) vibrational band can be detected around 866 cm'1 in biological or synthetic biomimetic apatites,
and the presence of this band indicates that some carbonate ions are not localized in regular apatitic
environments [179]. Also, ion exchange experiments have shown the possibility to exchange these
non-apatitic carbonate species with non-apatitic HPO4
2' ions.
Such ion exchange experiments were found to be fast phenomena (generally taking few minutes to
stabilize) and mostly reversible, therefore strongly suggesting surface rather than bulk processes. Most
importantly, 2D 13C–1H solid-state NMR analyses run on biomimetic apatites [172] showed the exis-
tence of a clear correlation between the non-apatitic carbonate species and water molecules [22].
Taking into account the circumstances of formation of apatite nanocrystals in biomimetic conditions,
a strong interaction of the nanocrystals surface with water molecules is indeed quite probable. 1H
solid-state NMR data could indeed be related to water molecules associated with bone apatite nano-
crystals – or their synthetic analogs [180,181]. This interaction may in fact play a role in the thermo-
dynamic stabilization of the nanocrystals surface (e.g. lowering of surface energy).
Complementary characterization information can also be obtained by Raman spectroscopy. This
information is then given by scattered photons of different wavelengths after the interaction between
the incident visible light and the sample [154,182]. A vibrational transition is Raman active if the
molecule/functional group changes its polarizability (i.e. tendency of the electron cloud of the mole-
cule/group to be distorted by an external electric field) whereas the selection rules for IR establish
a change on the dynamic dipole moment during the vibration [154,182,183]. Thus, in general, some
vibrational modes will be active in both spectroscopies, but others will be only Raman- or IR-active.
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Fig. 10. Details of the n3PO4 FTIR band for nanocrystalline apatites (wet and dried) and for OCPt.
Therefore, the combination of both spectroscopies can provide a complete vibrational description of
the system under study. Additionally, the use of dispersive Raman spectrographs [154,182] equipped
with a confocal microscope enables a very small sample area or volume to be analyzed (down to the
micron scale). Hence, this technique will be surface-sensitive when focusing with confocal microscope
to the surface of the sample [184,185]. In addition, for in situ experiments, Raman spectroscopy has
some advantages over FTIR including minimal sample preparation, the possibility of remote sensing,
and a low sensitivity to interference from water (since water molecules are weak scatterers of visible
light). This fact makes the technique particularly suitable for in-situ characterization of samples in
aqueous solutions [156,157].
Raman spectroscopy has then been demonstrated to be a powerful tool to analyze the structural,
compositional and physico-chemical properties of both synthesized nanocrystalline apatite and bio-
logical ones [163,186–188]. Raman spectra collected for a nanocrystalline apatite grown by thermal-
decomplexing batch precipitation [24] are represented in Fig. 11. As can be seen, the main peak
appearing at 961 cm'1 corresponds to n1PO4 mode [165] which, as described previously, was
observable as a weak shoulder in the IR spectra (Fig. 8). Conversely, the most intense IR absorption
band corresponding to the n3PO4mode is practically negligible in the Raman spectra (1000–1110 cm
'1).
Degenerated bending modes of phosphate groups, n4PO4 and n2PO4, emerge between 610–580 cm
'1
and 450–420 cm'1, respectively [165]. An interesting additional Raman feature in the case of highly-
nonstoichiometric nanocrystalline apatites is the presence around 955 cm'1 of a shoulder to the
n1PO4 peak [165,189–192], and this secondary peak is thought to be due to the signature of the non-
apatitic phosphate chemical environments as already evidenced by FTIR.
The presence of carbonate ions in the case of carbonated apatites is witnessed, by Raman spec-
troscopy, by the symmetric stretching of carbonate groups (n1CO3) appearing at 1070 (B-type) [187,191]
and 1103 cm'1 [187] (as a shoulder, A-type) in the spectrum b collected for particles grown in the
presence of 50 mM of sodium carbonate in the initial solution mixture. It can be clearly seen that B-
type carbonate substitutions are strongly favored instead of A-type. The type of carbonate site in
apatite is also distinguishable in Raman spectra through the n4CO3
2'mode (between 600 and 720 cm'1)
[191] although the signal is very weak in this example. Awonusi et al. demonstrated that the area ratio
of the band at 1070 cm'1 (n1CO3
2') and that at 960 cm'1 (n1PO4) is strongly correlated to the carbonate
content of apatite [191]. Moreover, the peak position and width of the n1PO4 band (960 cm
'1) strongly
depends on, respectively, the compositional characteristics of the synthetic HA and the degree of ionic
Fig. 11. Raman spectra collected for apatite nanoparticles precipitated by the thermal-decomplexing batch method without (a) and
adding (b) 50 mM Na2CO3 to the initial solution. The inset represents an enlarged view of the high-energy OH vibrations spectral
region. Bands at 1070 and 1103 cm'1 in spectrum b are related with carbonate ions occupying PO4 (B-type) and OH (A-type)
positions within the apatitic crystal lattice (see Refs. [165,187]).
ordering within the apatite unit cell [188,191]. In the example of Fig. 11 (spectrum b), the carbonate
incorporation causes a red-shift from 962 cm'1 (frequency reported for standard not-carbonated HA,
NIST [188,191]) to 958 cm'1. Raman spectra also provide valuable information about apatite hydroxyl
groups as well as aliphatic groups of organics molecules adsorbed and/or incorporated to the apatite
crystal lattice. In Fig. 11, the stretching vibration of OH groups (nOH) can be clearly seen at 3570 cm'1.
The intensity of this band decreases in spectrum b due to the replacement of some OH' by carbonate
groups. From the characterization of several biological apatites by Raman spectroscopy, it has been
concluded that the degree of ionic order in the apatite unit cell increases when increasing the degree of
hydroxylation, estimated as the area ratio of the nOH over the n1PO4 bands [188].
Considering all the above data, originating from complementary characterization techniques,
apatites nanocrystals (whether biological or their synthetic analogs prepared under physiologically-
inspired conditions) may most probably be described by an apatitic core (often nonstoichiometric)
and a structured “non-apatitic” surface hydrated layer containingwater molecules and rather labile ions
(e.g. Ca2þ, HPO4
2'
; CO3
2'
.) [4,105], as illustrated in Fig. 12.
The presence of this hydrated surface layer is thought to be responsible for most of the properties of
biomimetic apatites, and in particular their high surface reactivity in relation with surrounding fluids
(which is probably directly linked to a high mobility of ionic species contained within this layer, as
witnessed by fast surface ion exchange reactions). This reactivity may then explain, from a physico-
chemical viewpoint, the role of bone mineral in homeostasis in vivo.
One property linked to this peculiar surface state is the compound apparent solubility. Indeed,
experimental solubility studies shower that the determination of a constant solubility product (Ksp) for
nanocrystalline apatites was not possible, as it was found to depend on the amount of apatite dissolved,
and this peculiar behavior is known under the appellation “metastable equilibrium of solubility” (MES)
[193]. Each sample is thus in fact characterized by a series of Ksp values. Although the origin of this
behavior has not yet been clearly identified, the heterogeneity of composition within crystals (with
a surface composition different from that of the bulk) and the presence of strains (related to ion
substitutions and the presence of defects in the lattice) are most probably involved.
It is worthwhile remarking that the typical non-apatitic features were shown to progressively
disappear during the aging of the nanocrystals in solution [194,195]. This process was referred to as
“maturation” and has been related to the progressive growth of apatite domains at the expense of the
surface hydrated layer [194], which is probably thermodynamically-driven. It is thus possible to
prepare synthetic analogs to either “young bones (more precisely bone mineral)” or “more mature”
ones by selecting adequately the conditions of maturation, especially in terms of duration, tempera-
ture, relative concentrations and pH. This maturation process is indeed thought to be linked to the
metastability of such poorly-crystallized nonstoichiometric apatites, which may steadily evolve, in
solution, toward stoichiometry and better crystallinity [195–197]. Such evolutions then lead to limited
potentialities to undergo ion exchanges [194] or adsorption phenomena [198–200].
Fig. 12. Schematic model of a biomimetic apatite nanocrystal (a) and interaction with surrounding fluids (b). Reprinted with
permission from Ref. [4]. Copyright 2007 Nova Science Publishers.
This high surface reactivity of apatite nanocrystals can be exploited for the setup of innovative
bioactive materials, for bone tissue engineering applications and even beyond. The high ionic mobility
within the hydrated layer has for example been recently shown to allow the preparation of a new
generation of bioceramics by consolidating biomimetic apatites at “low” temperatures (e.g. at 150 !C by
spark plasma sintering, SPS), while preserving most of the characteristics of the initial powders, and in
particular their nanometric size, hydrated characters and nonstoichiometry [192,195,201]. Also, the
high surface reactivity of apatite nanocrystals can be exploited for enriching biomimetic apatite-based
materials with biologically-active ions like Mg2þ or Sr2þ [104,177,202] or with active molecules
[203,204], either using the bioceramic by itself (self-supported) or as a bioactive coating on bone repair
scaffolds or prostheses.
All the above statements show that the use of several complementary techniques is needed for
gaining an accurate idea of nanocrystalline apatites, whether biological or their synthetic analogs, and
many differences with stoichiometric HA can clearly be evidenced. Of special interest is the peculiar
surface state of apatite nanocrystals, which can be described as a hydrated organized but non-apatitic
metastable layer, and the presence of this layer (sometimes inappropriately called “amorphous” since
clear reproducible features can be observed by spectroscopy techniques) is thought to play a key role in
the high reactivity of bone mineral or of synthetic biomaterials based on apatite nanocrystals.
Beside spectroscopies, additional features on such nanocrystalline apatites can also be attained
through other techniques. AFM in particular allows imaging the surface of many samples (including
biomaterials) at the atomic scale in ultrahigh vacuum (UHV), ambient air and even liquids environ-
ments. It therefore may lead to complementary characterization details.
This microscopy is not based on the current as the Scanning TunnelingMicroscope (STM), but on the
detection of the tip–sample interaction force that allows to study non-conductive samples and
substrates [205]. The simplest imaging set-up is the contact mode, where the repulsive force between
the tip and the sample is kept constant. Then, the tip follows the sample surface giving a map of its
topography [205]. However, non-contact modes are commonly applied to very soft samples (such as
biological systems) and to true atomic resolution studies even in liquid environments [206].
In recent years, in situ AFM has been used to study the growth thermodynamics and kinetics of
several mineral systems such as calcite [207], barite [208] and gypsum [209] among others including
hydroxyapatite [149,210,211]. Onuma et al. proposed a cluster growth model for hydroxyapatite under
similar conditions as in the human body [149,211]. The authors estimated, as a function of supersat-
uration, the step kinetic coefficient and the edge free energy from the velocity of growth steps and the
variation in the normal growth rate, respectively. Since both values were found to be close to those of
protein crystals [211], authors concluded that the growth units of apatite crystals are clusters rather
than simple ions [211]. In situ AFM has also provided information about the hydrolysis processes of
other calcium phosphates such as dicalcium phosphate dehydrate (DCPD) and OCP [212,213] to HA in
the presence of aminoacids and/or citrate ions.
Surface structural properties of nanocrystalline hydroxyapatite/titanium coatings such as rough-
ness and porosity can also be analyzed by AFM at the nanometer level [214,215]. In addition, AFM can
be especially useful tomeasure the thickness of the HA films deposited on Ti substrates. The step height
between the HA film and the Ti substrate can be measured from the AFM images of partially covered
HA/Ti samples. In another case, these measurements have allowed to measure a thickness lower than
10 nm for nanostructured silver thin films partially deposited on flat Germanium substrates [216].
AFM also provides the unique opportunity to “visualize” in situ the interactions between biological
macromolecules and HA surface in aqueous environments at the nanometer scale [217]. For instance,
Jiang et al. demonstrated that AFM is a powerful tool to explore in detail the HA interface in contact
with citrate-containing solutions [218]. From in situ high-resolution AFM images, they proposed that
only a side carboxylate of citrate anions interacts with a calcium ion of the (100) HA face. Furthermore,
they observed that adsorbed citrate molecules are self-assembled on the HA surface by using their free
carboxylate and hydroxyl groups [218]. In the same way, AFM has been used to investigate the inter-
actions between HA surface and extracellular matrix proteins (i.e. bovine serum albumin (BSA) and
recombinant mouse amelogenin (M 179), which play an important role in the enamel apatite crystals
development [219]). AFM images collected before and after proteins adsorption are shown in Fig. 13.
The size of the adsorbed proteins indicated that albumin is bound to the HA surface as a monomer
whereas amelogenin is adsorbed forming bigger aggregates [219]. Furthermore, desorption process
using phosphate buffer has been also followed by AFM (Fig. 14). The images show that amelogeninwas
bound more strongly to certain crystal faces suggesting a more specific role for this protein in the
control of crystal morphology and growth [219]. Vázquez-Hernández et al. studied the adsorption of
bovine serum albumin (BSA) and fibrinogen (FGN) on nanocrystalline apatite synthesized by hydro-
thermal method [220]. In this case, AFM images showed ovoid-shaped adsorbed BSA molecules
whereas adsorbed FGN molecules were elongated with dimensions around 525 nm # 130 nm.
Therefore, they concluded that both proteins are denatured in the adsorption process since they change
their original shape and size [220].
4.3. Study of surface interactions
The non-apatitic environments of the hydrated layer of nanocrystalline apatites have been shown to
be responsible for several properties of the nanocrystals, especially their alteration upon ageing in
solution, as well as their ion exchange and adsorption abilities. Adsorption phenomena onto
Fig. 13. Tapping mode AFM images of maturation stage enamel crystals before and after the binding of BSA (b) and amelogenin (a)
and (c) crystals imaged under distilled water prior to the introduction of proteins to the fluid cell. Appearance of a typical crystal
5 min after the introduction of BSA (b) and aminogenin (d) proteins solution. Bands of BSA protein on the crystal surface are visible
and are indicated by the arrows. Reprinted with permission from Ref. [219]. Copyright 2001 American Chemical Society.
biomimetic nanocrystals play in particular an important role in the biomineralization process in living
organisms and in the regulation of bone mineral turnover through protein and drugs adsorption and
release. Adsorbate–mineral interactions at the surface can be, for instance, well evidenced using
different spectroscopic methods such as FTIR, solid state NMR or Raman.
4.3.1. Ion exchange on nanocrystalline apatites
Concerning ionic mobility of the nanocrystalline apatites surface, the ions of the hydrated layer
constitute a pool of loosely bound mineral ions which can be easily replaced by other ions from the
surrounding solution. The ionic mobility in the surface of apatitic nanocrystals appears to be strongly
dependent on the nature of the ions, on the composition of the apatite and on its maturation stage [22].
The exchange reactions result from the replacement of one ion of the hydrated layer by one ion from
the solution, sometimes observable by FTIR spectroscopy, without major other alteration of the solid
composition (especially no change in apatite stoichiometry and XRD patterns [177]). These reactions
are very rapid, and the exchange equilibrium is reached within few minutes. They can generally be
mathematically modeled using a Langmuir-type isotherm. The exchange reactions do not however
appear as a reversible equilibrium like in regular Langmuir-type adsorption, as the exchanged ions
cannot be removed from nanocrystals surface by simple dilution of the exchange solution, or subse-
quent washing of the solids. However, the exchanged ions can be almost totally removed (back-
exchanged) by contacting the nanocrystals with calcium or phosphate solutions (or other mineral ions
which may replace them in the hydrated layer such as anions like carbonate or cations like magnesium
or strontium for example) [22,177,196].
The affinity constant and the maximum adsorbed amount depend on the nature of the ions. Both
anionic and cationic species can be exchanged [22] but not all the possibilities of these exchange
reactions are known yet. The first experiments to be reported concerned essentially bivalent cations
and anions. Moreover, it has been found that some monovalent ions like Naþ and Kþ could not be
incorporated [158,221]. As an example of anionic exchange, HPO4
2' ions from nanocrystalline apatites
can be replaced by carbonate ions from a surrounding solution. The exchange of HPO4
2' by CO3
2'
results in a decrease of the intensity of the FTIR band observed at 534 cm'1 and attributed to HPO4
2'
labile ions localized in non-apatitic environments, these results confirm that only non-apatitic
(surface) species participate in the exchange reaction [196,222]. Cationic exchanges are also possible
and exhibit similar characteristics as the anionic exchanges. For example cationic substitution of Mg2þ
and Sr2þ has been studied by several authors, according to the particular biological interest of such
Fig. 14. Tapping mode AFM images of same crystals imaged 10 min after the exchange of the BSA (a) and aminogenin (b) protein
solutions with phosphate buffer solutions. In the case of BSA, there is no evidence for proteins remaining on the mineral surface,
however, despite of the aminogenin protein has been removed from the upper surface of the crystal, it remains bound to the sides
(marked with arrows). Reprinted with permission from Ref. [219]. Copyright 2001 American Chemical Society.
ions. Ionic exchanges of such ions with calcium within the hydrated layer have been suggested with
a substituting ratio close to 1:1. A greater affinity of both carbonated and non-carbonated apatites was
found for strontium as compared to magnesium [177,194].
Moreover the ion exchange properties of nanocrystals appear to be strongly dependent on the
composition of the hydrated layer and on ageing. The ability to exchange surface ions with ions from
the solution decreases considerably with the maturation state of the apatitic nanocrystals. The
hydrated layer progressively decreases in proportion to the crystals maturation, and so does the
amount of exchangeable ions [22,196]. The ion exchange mechanism depends also on the composition
of the nanocrystals hydrated layer. It has been published that for a given exchanging ion such as
magnesium and strontium, a greater exchanged amount can be reached on carbonated nanocrystalline
apatites compared with non-carbonated one. CO3
2' ions are well known to act as apatite-growth
inhibitors [223] which could explain the more developed hydrated layer on carbonated nanocrystals
surface [177].
Another characteristic of nanocrystalline apatites is their ability to progressively incorporate several
elements into the apatitic lattice (bulk), depending on the composition of the surrounding solution.
Thus concerning ionic exchange on nanocrystalline apatites, two types of ions can be distinguished.
Some ions, like Mg2þ, may exchange easily with calcium ions from the hydrated layer but they cannot
massively penetrate in apatite domains: therefore such ions always remain exchangeable indepen-
dently of the maturation stage of the apatites. On the contrary, other ions like Sr2þ can be incorporated
into the surface layer and progressively penetrate in the apatite domains (bulk) and then cannot be
removed without destruction of the crystals [4,22,196]. Strontium substitution for calcium leads to
a linear variation in the cell parameters and in the infrared adsorption bands positions of the hydroxyl
and phosphate groups, coherent with the increase of the ionic radius. The position of the Raman band
attributed to n1 PO4
3' at around 963 cm'1 in strontium-substituted apatites decreased linearly to
949 cm'1 at full Sr-substitution [224,225].
4.3.2. Organic molecules adsorption on nanocrystalline apatite
In addition to these aspects on ion exchange abilities, nanocrystalline apatites have the ability to
adsorb organic molecules such as proteins or drugs. Organic molecules (e.g. bioactive ones) often
exhibit a high binding affinity for calcium phosphate surfaces, but if adsorption studies of such
molecules onwell-crystallized HA arewell described [226–229], very few studies have been performed
on the adsorption of organic molecules on nanocrystalline apatites despite physico-chemical features
much closer to those of bonemineral. As for ion exchanges, the adsorption isotherms are generally well
described by the Langmuir model, as it has been published for proteins as bovine serum albumin (BSA)
[200,230], or o-phosphoserine [231], although the adsorption on apatitic surface of some aminoacids
as serine, or simple molecules weakly interacting with apatite, can be more adequately described by
a Freundlich type isotherm [231]. The adsorption process is explained by the replacement of some ions
from nanocrystals surface by some charged/polarized end groups of organic molecules from the
surrounding solution. Negatively-charged molecules are considered to bind to calcium sites (generally
with simultaneous release of phosphate ions from the hydrated layer to the solution) while positively-
charged ones bind to phosphate sites (generally with simultaneous calcium release). For example, the
adsorption reaction of bisphosphonates molecules as antiresorptive agents can be described by an ion
exchange process between phosphate ions on the surface of the apatitic nanocrystals and phospho-
nates groups of the active adsorbing molecules. Solid state NMR provides information on the nature
and state of the adsorbed species at the apatite surface [232,233]. The very high affinity of phospho-
serine for apatite surface compared to that of serine can be explained by the existence of the phosphate
endgroup on the molecule which can interact strongly with the apatite surface, as evidenced by FTIR
spectra of the samples after adsorption, where a change in FTIR bands position associated with
carboxylate vibrations indicate the strong interaction with the apatitic surface (Fig. 15) [231]. The
surface adsorption reaction of organic molecules is obviously influenced by several solution parame-
ters such as temperature, pH, and ionic contents in the surrounding solution. Several processes can
disturb the adsorption equilibrium on apatitic nanocrystals: the possible precipitation of calcium (or
phosphate) salts formed with the adsorbed molecule, the dissolution equilibrium of the solids and/or
hydrolysis reactions of apatitic surface. For example, the mechanisms involved in protein and peptides
adsorption on inorganic substrate is in fact a complex process consisting of many events, including
protein conformational changes and protein–protein interactions [230,234].
Apart from the associated ion exchange phenomenon, the process of adsorption of organic mole-
cules on nanocrystalline apatites does not differ strongly from well-crystallized hydroxyapatite;
however an interesting aspect is the variation of the adsorption parameters with the characteristics of
the nanocrystals. As for ion exchange, the adsorption properties of the organic molecules are strongly
dependent not only on the chemical properties of such molecules, but also on the nature of apatitic
nanocrystals and maturation stage, as could be observed for proteins as BSA [200] or drugs as
bisphosphonates molecules [232]. Experimental results indicate an increase of the affinity constant
and a decrease of the amount adsorbed as maturation time increases. The increase of the affinity
constant with maturation may be correlated with an increase of interfacial energy of nanocrystals
duringmaturation in aqueousmedia. Indeed, the hydrated layer probably reduces the surface energy of
the nanocrystals in aqueous media, and thus molecules adsorption for more mature systems should be
energetically favored [22,232]. The decrease of the number of adsorption sites with maturation time
can be interpreted as a decrease of potentially exchangeable ions in the hydrated layer or a change in
the equilibrium constants [22]. It can be seen that the ability of a poorly-crystalline apatite to adsorb is
related to the number of its non-apatitic surface sites and its low crystallinity. As the adsorption process
can be explained by ion exchange process at the surface of the apatitic support, the amount of organic
molecules adsorbed could be related to the amount of labile mineral ions available in the hydrated
layer and then to the extent of the hydrated layer. As the maturation proceeds, the amount of such
exchangeable species diminishes and the adsorption capacity of the solid decreases.
As for ion exchange, the reaction appears irreversible with respect to dilution, as observed for
proteins or active agents [232]. After the adsorption event, no desorption should be expected by simple
dilution of the adsorption solution or even uponwashing of the samples, except for faint release effects
due to the dissolution of the apatite. This behavior could be useful in view of the controlled release of
such agents from apatitic biomaterials in vivo. Indeed, generally, bioactive molecules such as growth
factors or drugs are incorporated in biomaterials by simple impregnation followed by drying, and such
associations do not allow the chemical bonding of the organic molecules and thus the release rate from
the solids is often difficult to control [235]. On the contrary, adsorption leads to stable association and
Fig. 15. FTIR spectra of poorly crystalline apatitic samples adsorbing serine and phosphoserine at pH ¼ 7 and 20 !C (a) untreated
(b) treated with deionized water (c) treated with 0.1 M serine solution (d) treated with 0.1 M phosphoserine solution (e) phos-
phoserine calcium salt. Reprinted with permission from Ref. [231]. Copyright 2001 Elsevier.
control of the amount of bioactive molecules contained in the solid implant, and thus of the dose
released [199,204,236–238]. Moreover as adsorption properties of the organic molecules are strongly
dependent on the chemical and structural characteristics of apatitic nanocrystals, the release rate is
also related to the physico-chemical properties of the apatite samples. For example some authors show
that the coating of sintered biphasic calcium phosphate granules (hydroxyapatite and b-tricalcium
phosphate) with nanocrystalline apatites improves growth factors adsorption, such as with bone
morphogenetic protein BMP-2 [204], and controls its release rate, as only a low quantity of protein is
spontaneously released in cell culture medium during the first weeks. Similarly Palazzo et al. [239]
show that adsorption and release kinetics of three drugs (cisplatin, alendronate and di(eth-
ylendiamineplatinum)medronate) are controlled by the surface properties of the nanocrystalline
apatitic support such as surface area and surface charge, as well as the charge on the adsorbed
molecules and their mode of interaction with the apatitic surface. These properties of biomimetic
nanocrystalline apatites suggest the possibility to functionalize the surface of such nanocrystals with
different linking agents, such as bisphosphonates for example, to anchor biologically active molecules
for specific therapeutic application [237], or to improve the biocompatibility of bone-implantable
biomaterials for hard-tissue engineering and regeneration technologies [240]. The use of nano-
crystalline apatites as drug delivery carriers will be further discussed in Section 4.1.
5. Advanced biomedical applications of nanocrystalline apatites
5.1. Drug delivery and surface functionalization
Materials can interact with biomolecules as well as with living systems and these interactions can
be used to develop new materials and technologies [241]. The main driving force behind the use of
apatites as materials for health care is their chemical similarity to the mineral component of
mammalian bones and teeth, as previously explained in details. As a result, in addition to being non-
toxic, they are biocompatible, not considered as noxious foreign materials in the body and, most
importantly, they both exhibit a bioactive behavior and may integrate into living tissues by the same
processes as the ones that are active in remodeling healthy bone. This leads to an intimate physical-
chemical bond between the implants and bone, termed osteointegration. More to the point, calcium
phosphates are also known to support osteoblast adhesion and proliferation. Even so, the major
limitations to use apatites as load-bearing biomaterials are their mechanical properties; namely, they
are brittle with a poor fatigue resistance [12]. The poor mechanical behavior is even more evident for
highly porous ceramics and scaffolds, as porosity greater than 100 mm is considered a requirement for
proper vascularization and bone cell colonization [12]. That is why, in bone-related applications,
calcium phosphates are used primarily as fillers and coatings [242]. Moreover, apatites may find several
other biomedical applications such as for drug delivery [243]. Numerous bioactive molecules can
indeed be associated to calcium phosphates, including proteins, aminoacids, antibiotics, growth
factors, anticancer and antiosteoporosis drugs [130,237,239,240,243–245]. However, so far, only very
few studies have been carried out to understand the adsorption behavior of therapeutic molecules on
apatitic calcium phosphates, especially nanocrystalline apatites.
As drug carriers, apatite nanoparticles exhibit some advantageous properties: i) favorable biode-
gradability and biocompatibility properties in general; ii) soluble and less toxic than silica, quantum
dots, carbon nanotubes, or magnetic particles [246]; iii) more stable/robust than liposomes, which
predisposes them for a more controlled and reliable drug delivery. Contrary to liposomes and other
micelle-based carriers, which are subject to dissipation below specific critical concentrations (which
presents a clear obstacle upon injecting them into the bloodstream), calcium phosphates-based
systems and particularly those with Ca/P molar ratio close to the one of HA, are negligibly soluble in
blood, which is naturally supersaturated with respect to HA; iv) higher biocompatibility and pH-
dependent dissolution compared to polymers [247].
Furthermore, nanocrystalline apatite nanoparticles may hold larger load amounts of drugs because
of their larger specific surface areas than coarse particles. The dissolution of calcium phosphates is
accelerated at low pHmedia, which are typically found in endolysosomes and in the vicinity of tumors,
providing an advantage in the delivery of drugs into malignant zones or cell organelles. They are also
able to permeate the cell membrane and dissolve in the cell, whichmakes them an attractive candidate
for gene delivery agents [248,249].
Another important advantage of calcium phosphates is the low production costs and excellent
storage abilities (not easily subjected to microbial degradation). As previously explained, the prepa-
ration of nanosized calcium phosphates is not a complicated task, although it should be undergone
with care. Unlike most other ceramics, nanosized calcium phosphates can be prepared in situ, under
ambient conditions, in awide array of morphologies, from spheres to platelets to rods to fibers. Calcium
phosphates can also be prepared with a variety of phase compositions thereby enabling fine tuning of
the dissolution properties in vivo.
Bioactive molecules often exhibit a high binding affinity for calcium phosphate surfaces. Generally
the adsorption equilibrium of such drugs strongly interacting with an apatitic surface can be satis-
factorily described by a Langmuir isotherm, a behavior similar to that presented by proteins and
aminoacids [119,200,219,220,250,251], as explained in Section 2. Negatively-charged molecules are
considered to bind to calcium sites and positively-charged ones to phosphate sites. The interaction of
organic molecules and calcium phosphate surfaces depends on the nature of the molecules. For
example, it has been published that, in the case of antibiotics, those containing carboxylic groups like
cephalothin interacted better with the apatite coating applied onto titanium implants [252]. Some
studies have shown that carboxyl-containing molecules are good binders of calcium sites [250,253]. In
the same way, adsorbate–adsorbent interactions can take place during protein adsorption, depending
on the protein structure and the nature of the surface of the adsorbent [228]. Few works show a strong
affinity of growth factors for apatitic surfaces, enhanced in the simultaneous presence of calcium ions
in the solution as in the case of the adsorption of other proteins [254,255].
The study of interactions between bonemorphogenetic proteins (BMPs) growth factors and apatitic
surfaces is of great biological and medical interest as BMPs have been attempted to be applied for the
reconstruction of bone defects resulting from trauma, surgical resection of tumors, and congenital
anomalies in orthopedic and maxillofacial surgery. A computed theoretical modeling based on the
interactions of the (001) HA surface with functional groups of BMP-2 growth factor [227] has evi-
denced three types of interactions: an electrostatic interaction of charged COO' groups from the
protein with Ca2þ ions on the apatite surface, and water-bridged H-bonds between OH and NH2
residues of BMP-2 and with phosphate ions from the apatite crystal surface [204].
5.1.1. Nanocrystalline apatites: application to drug delivery
As previously mentioned, one of the most efficient ways to improve the bone forming ability of
biomaterials is their association with bone morphogenetic proteins [204]. Generally, bioactive mole-
cules such as growth factors are incorporated in biomaterials by simple impregnation followed by
drying, and the type of bondingwith the substrate and the release rate are often undetermined [252]. It
is suspected that such associations do not allow the chemical bonding of the growth factor to the
biomaterial and thus the release rate is often difficult to control. For example, precipitation and
clustering of the growth factor molecules may occur and the release is only determined by local
dissolution and diffusion rules [204]. In some cases, the uncontrolled release of growth factors has been
related to an accelerated resorption of bone tissue and of the implant [204]. Since growth factors agents
can stimulate the degradation as well as the formation of bone (depending on their local concentra-
tions), they could impair the osteoconductivity of the coated-implant surface [256]. In the same way,
local and slow administration of antineoplasic drugs like methotrexate (MTX) is also useful to avoid
systemic side effects, and because its time effect (the sensitivity of cells to this drug increases with
time) is greater than its dose effect [257].
On the contrary, adsorption on apatitic surfaces (as opposed to simple impregnation) leads to
a stable association and control of the amount of bioactive molecules contained in the solid implant,
and thus of the dose released. Generally, the release is rather low because most of the bioactive
molecules adsorbed are irreversibly bound and they are not spontaneously released in a cell culture
medium [226] as explained above. They can only be displaced by mineral ions and/or soluble proteins
with a stronger affinity for apatite surfaces but in a predicable manner (following an ionic back-
exchange process already discussed), or by cell activity [226]. This characteristic has been observed
for various growth factors like bone morphogenetic protein (BMP-2) or vascular endothelial growth
factor (VEGF) [204,257], and for others bioactive molecules such as antiosteoporosis agents [258,259]
and anticancer drugs [236,260]. Fig. 16 illustrates antibiotics release incorporated in apatitic calcium
phosphate coatings on titanium implant using biomimetic method [252]. A local release system of
antibiotics could be used to prevent post-surgical infections favoring early osteointegration of pros-
thesis. Some of the antibiotics containing carboxylic groups in their chemical structure, like cephalo-
thin, were better adsorbed than others into calcium phosphate biomaterials. These molecules are
slowly released from the carrier [253]. Moreover the high binding capability of the apatitic support for
a wide range of therapeutic agents allows its surface functionalization with linking agents, such as
bisphosphonate molecules, to anchor biologically activemolecules which can be released, breaking the
linkage as a consequence of external stimuli or internal chemical factors, such as pH and ionic force
variation due to physiological or pathological biological process [103,240]. For example, some works
have investigated the adsorption and “smart release” of antitumoral platinum complexes containing
bisphosphonate molecules onto apatitic nanocrystals as bone specific drug delivery devices to be used
for the treatment of bone tumors upon local implantation [237].
The adsorption and release of bioactive molecules are strongly affected not only by the chemical
properties of the drug molecule, but also by the chemical and structural characteristics of the apatitic
substrates. For example the release rate of cisplatin anticancer drug can be controlled by use of a better
crystallized apatite phase for a faster release rate or a less crystalline material for a slower rate [236].
Similarly the coating of sintered biphasic calcium phosphate granules (HA and b-TCP) with nano-
crystalline apatite increases the rate of BMP-2 growth factors adsorption [204]. Only a low quantity of
protein was spontaneously released in cell culture medium during the first weeks (Fig. 17).
Palazzo et al. have compared the behavior of metal-based drugs to that of a classical organic drug
(alendronate), evaluating the effect of the drug molecule overall charge in influencing the drug affinity
for apatite nanocrystals with variable structural and chemical different properties [239]. The adsorp-
tion and release of cisplatin, alendronate and di(ethylendiamineplatinum)medronate have been
investigated using two biomimetic synthetic apatite nanocrystals materials with either plate-shaped
or needle-shaped morphologies and with different physico-chemical surface properties. The apatite
surface area and surface charge (as well as other parameters such as Ca/P ratio etc.), as well as the
charge on the adsorbed molecules and their mode of interactionwith the apatite surface, influence the
Fig. 16. Antibiotic release from carbonated apatitic calcium phosphate coatings on titanium implants into phosphate buffered saline
at pH 7.3. Reprinted with permission from Ref. [252]. Copyright 2004 Elsevier.
adsorption and release kinetics of the three drugs investigated. The results demonstrated that apatite
nanocrystals and antitumor drugs can be selected in such away that the bioactivity of the drug–apatite
conjugate could be tailored for specific therapeutic applications.
The adsorption of two different platinum complexes with cytotoxic activity, {ethyl-
enediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate (A) and bis-{ethylened
iamineplatinum(II)}medronate (B), on the synthesized biomimetic nanocrystals has been investigated
by Iafisco et al. [237]. Both complexes contain a geminal bisphosphonate but, in addition, complex A
contains a charged ammonium group.
This structural difference dramatically affects the affinity of A and B toward apatite nanocrystals,
complex A having a greater affinity for calcium phosphate nanocrystals. The release profiles of the
platinum complexes from the apatite nanoparticles follow an inverted trend (complex B > complex A)
when compared with the adsorption process. Most probably the less effective desorption in the case of
complex A could be due to the aminic group present on the bisphosphonate which remains anchored to
the apatite matrix, coordinating and holding some of the ethylenediamineplatinum (Pt(en)) residues.
Unmodified and apatite-adsorbed Pt complexes were tested for their cytotoxicity toward human cervix
carcinoma cells (HeLa). The apatite-loaded Pt complexes were more cytotoxic than the unmodified
compoundsAandBand their cytotoxicitywas comparable to thatof dichloridoethylenediamineplatinum
[PtCl2(en)] thus indicating a common active species. The above results demonstrate that apatite nano-
crystals and antitumor drugs can be conjugated in such away to yield a smart bone filler delivery system,
acting both as bone substitutes and as platinum drug releasing agents with the final goal of locally
inhibiting the tumor re-growth and reducing the systemic toxicity. The one here described not only can
ensure a prolonged release of active species but also improve the performance of the unmodified drug.
Moreover, these results suggest the possibility of using the chemical–physical differences of apatite
nanocrystals, above all degreeof crystallinity, crystal size andsurface area, inorder to strongly tailor thePt
complex release kinetics.
Considering the biomimetic apatite nanocrystals functionalization effects, an attracting goal could
be to obtain a drug delivery process characterized by a stimuli responsive kinetic. This aim induces to
functionalize the surface of apatite nanocrystals with different linking agents, such as bisphospho-
nates, to anchor biologically active molecules which can be released breaking the linkage as a conse-
quence of external stimuli or internal chemical factors, such as pH and ionic force variation due to
physiological or pathological biological process.
Fig. 17. Cumulative release of BMP-2 in DMEM complete culture medium from adsorbed BMP-2 on nanocrystalline-apatite coated
and uncoated biphasic calcium phosphate. Reprinted with permission from Ref. [204]. Copyright 2009 John Wiley & Sons, Inc.
5.1.2. Example: bisphosphonates interaction with nanocrystalline apatites
Bisphosphonates (BPs) are well established as an important class of drugs for the treatment of
common skeletal disorders including osteoporosis. BPs were first studied over 30 years ago as synthetic
analogous stable of inorganic pyrophosphate inwhich the oxygen bridge has been replaced by a carbon
with various side chains (P–C–P) (Fig. 18). This substitution makes bisphosphonates resistant to bio-
logical degradation and therefore suitable for clinical use [261,262]. Their mode of action are at the
same time physico-chemical effects and cellular effects: like pyrophosphate, BPs present a high affinity
to adsorb onto bone mineral, and thereby prevent mineral dissolution and bone resorption, inhibiting
osteoclasts activity directly and/or indirectly. BPs have two additional substituents in their molecule
not present in pyrophosphate, R1 and R2, attached to the germinal carbon (Fig. 18), which may
significantly affect both themineral affinity and the pharmacological activity [263]. The ability of BPs to
bind to bone mineral is increased when the R1 functional group is able to co-ordinate to calcium, as
hydroxyl group (OH) [261,262]. Varying the R2 functional group can influence antiresorptive potency,
those containing a nitrogen atomwithin a heterocyclic ring (such as risedronate, zoledronate) have the
most potent antiresorptive effect [229,264]. Although the detailed mechanism of action of BPs has not
been fully elucidated, it is clear that at the tissue level all active BPs inhibit bone resorption, bone
turnover, and therefore, bone loss [261].
The classic BPs treatment is the systemic way by oral administration or intravenous injection.
However, undesirable side-effects like fever [265], ulcers [266,267] or osteonecrosis of the jaw
[267,268] are commonly observed by systemic use of BPs. Moreover low bioavailability is commonly
observed for oral administration [269]. In order to avoid these adverse effects and to increase BPs
bioavailability, the development of strategies for local administration of BPs within osteoporotic sites
becomes even more interesting.
While calcium phosphate ceramics are commonly used for biocompatible drug carriers, very few
studies have been focused on the development of bioactive implant based nanocrystalline apatites for
BPs local release. Some authors have recently shown that calcium deficient apatites were appropriate
carriers for such antiresorptive drugs, in which the apatitic nanocrystals/BP association can be
Fig. 18. Structure of the inorganic pyrophosphate and its synthetic (organic) analog bisphosphonate (BP). Examples of
bisphosphonates, risedronate and zoledronate: well established antiresorptive agents for the prevention and treatment of post-
menopausal osteoporosis.
chemically controlled and well evidenced by spectroscopic method [270,271]. Osteointegration of
association calcium phosphate matrices and BP was found to be BP concentration-dependent
[272,273], thus nanocrystalline apatite has been shown to be effective for loading and releasing BP
at doses that can inhibit excessive bone resorption without affecting osteoblasts [274]. For example
recent studies report on the adsorption of risedronatemolecules in solution on nanocrystalline apatites
powders [271]. NMR studies confirm the uptake of risedronate adsorbed by the solid surface. The
change observed for the 31P environment of the adsorbed phosphonates, with respect to the native
species, could be due to a local disorder induced by a strong interaction with the apatite surface,
particularly calcium ions. The analysis of the solutions obtained after adsorption revealed that the
binding of risedronate ions was accompanied by the displacement of phosphate ions from the mineral
surface. Similar observations were noted for zoledronate bound calcium deficient apatites [270]. When
zoledronate was grafted onto calcium phosphate powders, the adsorption process was associated with
the release of phosphate ions in the solution from the apatitic surface. The 31P CP-MAS solid state NMR
spectra recorded for nonstoichiometric apatite phases showed the presence of the BPsmoiety as a large
peak (Fig. 19). On the basis of these observations, it can be postulated that BPs species in solution
participate to an ionic exchange process with active mineral ions on the nanocrystals surface, partic-
ularly phosphates and/or carbonates, which share the same ionic sites [270,271]. The higher adsorption
capability observed for the nanocrystalline apatites, compared to well-crystallized HA, was attributed
to the presence of a well developed hydrated layer with relatively-mobile mineral ions at the surface of
the nanocrystals corresponding to non-apatitic environments (phosphates and carbonate groups) at
their surface [271], as explained in Section 2. In this context, the main parameter governing the release
of BPs adsorbed onto nanocrystalline apatites seems to be phosphate concentration in the desorption
medium, or other mineral ions which may replace them in the hydrated layer with release kinetics
compatible with the inhibition of bone resorption [233]. This suggests that nanocrystalline apatites
based delivery systems are able to precisely control BPs release by adjusting the properties of the
carriers. Thus nanocrystalline apatites based biomaterials appear to be good candidates for hard tissue
repair with a local action of these antiresorptive agents at the main osteoporosis induced fracture. Such
strategies open the door to entire classes of new treatments.
5.2. Coatings
Commercially pure titanium (cpTi) and Ti–6Al–4V alloys are the most commonly used metallic
implant materials, as they are highly biocompatible materials with good mechanical properties and
corrosion resistance [275,276]. The biocompatibility of titanium implants is attributed to the stable
Fig. 19. 31P CP-MAS NMR spectrum of zoledronate-modified calcium deficient apatite (CDA). Reprinted with permission from Ref.
[270]. Copyright 2005 Elsevier.
oxide layer (with a thickness of 3–10 nm) that spontaneously forms when titanium is exposed to
oxygen [277]. This reaction prevents the formation of fibrous tissue around the implant, and creates
direct contact to osseous tissue. However, when applying Ti(O2) as implant material, a non-
physiological surface is exposed to a physiological environment. Nevertheless, by generating
a coating onto a titanium surface that mimics the organic and inorganic components of living bone
tissue, a physiological transition between the non-physiological titanium surface and surrounding
bone tissue can be established. In this way, the coated titanium implant functions as scaffold for
improved bone cell attachment, proliferation and differentiation. Such a coating is supposed to further
enhance early and strong fixation of a bone-substituting implant by stimulating bone formation
starting from the implant surface. As such, a continuous transition from tissue to implant surface can be
induced. Consequently, research efforts have focused on modifying the surface properties of titanium
to control the interaction between the implant and its biological surrounding. As mentioned previ-
ously, apart from the living cells and the collagenous extracellular matrix themain constituent of bones
and teeth is nonstoichiometric calcium phosphate apatite and the ideal surgical implant would be
made from the samematerials. However (hydroxy)apatite is weak and brittle, making them unsuitable
for replacing parts of the body. To eliminate this problem, it was suggested that the titanium implants
could be improved by coating them with apatite. This approach would combine the mechanical
strength of titanium with the biological properties of biomimetic apatite.
Calcium phosphates coatings for orthopedic and dental implants were introduced by de Groot and
Geesink [278,279]. Since then numerous reports have been published about the osteoconductive
properties of calcium phosphates -coated implants (osteoconduction refers to the ability of a bioma-
terial to support the growth of bone over its surface). These apatite coatings are described to induce an
increased bone-to-implant contact [280,281] to improve the implant fixation [282], and to facilitate the
bridging of small gaps between implant and surrounding bone [283]. The calcium phosphates-layer
guides bone growth along the implant surface, and as a result bone formation now occurs from
both the surrounding tissue and the implant surface, in which calcium phosphates functions as
a physiological transition between the non-physiological titanium surface and surrounding bone.
The application of apatite on titanium is restricted because of failure at the metal-coating interface
leading to loosening of implants [284]. To improve the bonding strength of the coating, many methods
have been tested. So far, the most successful method to apply calcium phosphates coatings to implants
has been theplasma-spraying technique, due to its highdeposition rate and the ability to coat largeareas
[285,286]. Plasma-spraying is a technique inwhich a so-called plasma gun creates an electric arc current
of high energy between a cathode and an anode. An inert gas is directed through the space between
these electrodes and subsequently the arc current ionizes the gas and plasma formed. The electrons and
ions in this plasma are separated form each other and are accelerated toward the cathode and anode,
respectively. These rapidlymovingparticles then collidewith other atomsormolecules in the gas,which
results in expansion owing to the temperature increase. Then, a plasma flame is formed that emerges
form the gun toward the substrate at velocities approaching or exceeding the speed of sound. After,
hydroxyapatite ceramic powder particles are fed into plasmaflame. Theparticlesmelt and are deposited
on the substrate at which the gun is aimed. The quality of plasma-sprayed coatings can be influenced by
several parameters, such as the temperature of the plasma, the nature of the plasma gas, the particle size
of the powder and the chemical nature of the ceramic powder. In this way the apatite coating deposited
is quite different from bone mineral apatite. In fact, during this procedure the overheating and melting
can change the synthetic apatite powder [287], leading for example to its partial decomposition.
The osteoconductive and bone-bonding behavior of plasma-sprayed coatings was assessed by
numerous studies. However, it should benoted that, despite recent advances especiallywith low-energy
plasmas which were not much reported as yet, the chemical composition of plasma coatings generally
involve a mixture of several phases (including amorphous calcium phosphate in particular), not always
in a reproducible manner. Therefore, researchers have been continuously inspired in the past two
decades to explore alternative or complementary techniques for deposition of coatings onto an implant
surface. Various deposition methods have been proposed, including magnetron sputtering [288,289],
electrophoretic deposition [290], hot isostatic pressing, sol–gel deposition [291], pulsed laserdeposition
[292], biomimetic deposition [293], ion beamdynamicmixing deposition [294], electrospray deposition
[281], electrolytic deposition induction heating deposition from solution [285]. Other methods
involving hydrothermal treatment have also beenused, but its accomplishment commonly needs a two-
step treatment. First, a surface containing calcium and phosphorus ions is produced by any other
techniques such as anodic oxidation [295],micro-arc oxidation [296] or plasma spraying [297]. Then the
obtained samples are hydrothermally treated in an aqueous medium (water or SBF) to form apatite
phase. Such hydrothermal treatment method is complicated and increases cost and time. To overcome
these problems Hu et al. reported a one-step hydrothermal process with apatite suspension to realize
stable and uniform coating on a titanium surface [298]. Change of surface chemistry, surface
morphology of samples, and structure of formed nano-apatite were investigated. The concentration of
hydroxyl groups increased after hydrothermal treatment and the ability of the titanium surface to form
nano-apatite was enhanced by increasing the hydrothermal treatment temperature and time. The
bonding strength of the formed nano-apatite coating, examined by an ultrasonic cleaning process, was
higher than that of apatite coating generated directly by suspension deposition.
In addition to pure calcium phosphates, many different biologically functional molecules can be
immobilized onto titanium surfaces to enhance bone regeneration at the interface of implant devices.
However, most techniques used to prepare (inorganic) hydroxyapatite coatings are performed either at
extremely high temperatures or under non-physiological conditions, which preclude the incorporation
of biomolecules. The recent investigation trend has attempted to avoid this difficulty by adsorbing
biological agents onto the surfaces of preformed inorganic layers [299,300]. However, these superfi-
cially adsorbed molecules will be rapidly released in an uncontrollable single burst upon implantation
[301]. Hence, coating procedures that incorporate biomolecules into the apatite coating create a more
sustained release profile and are therefore of high interest [302]. In this way, the molecules can both
sustain their biological activity for a considered period of time and support the mechanical properties
of the coating in case of structural ECM components such as collagen [303]. Both the biomimetic and
electrospray deposition (ESD) process are among the most promising techniques, for generating
organic–inorganic composite coatings on implant materials, and for depositing a nanostructured
apatite coating due to their physiological process conditions [304,305]. ESD involves atomization of
a precursor solution by applying a high voltage to the liquid surface, which then disperses into an
aerosol spray of micro-sized charged droplets (<10 mm). This is accomplished by pumping the solution
through a nozzle. Usually a spherical droplet is formed at the tip of nozzle, but when a high voltage is
applied between nozzle and substrate, this droplet transforms into a conical shape and fans out form
a spray of highly charged droplets. These charged droplets are attracted towards a grounded substrate,
where a thin biofilm is formed after solvent evaporation. ESD technique has several advantages: very
simple and cheap set-up; high deposition efficiency, since the electric field directs charged droplets to
the substrate; control over the coating composition and the possibility to tailor the morphology of the
deposited coatings [306–308]. Leeuwenburgh et al. [281,308] demonstrated moreover the ability of
ESD to produce calcium phosphates coatings, using Ca and P precursor salt solutions bymixing them at
the spraying nozzle. Thian et al. [309] used the ESD for the deposition of biomimetic apatite nano-
crystals onto titanium substrates as uniform coatings at room temperature, using an apatite suspension
as the precursor solution. These apatite coatings triggered early apatite precipitation process in acel-
lular simulated body fluid and furthermore human osteoblast cells were observed to attach well on
these coatings, with clear evidence of well-formed actin stress fibers and vinculin adhesion plaques.
Thus, these results indicated the enhanced in vitro bioactivity of nanocrystalline apatite thin coatings.
It is worth noticing that caution should always be taken when directly comparing the success rates
of these coating techniques without a proper understanding of the physicochemical nature of the
specific calcium phosphates coatings. Generally, the conclusions about the biological/clinical perfor-
mance of coatings cannot be made without a complete set of characterizations that enable correlation
of material properties to biological response [310]. Clinically, each application demands specific
requirements, and in that respect the wide range of available coating techniques offers the possibility
to select the most appropriate deposition method for each specific implant application.
5.3. Medical imaging
As mentioned previously, nanocrystalline apatites are nano-sized materials and the constitutive
nanocrystals exhibit a highly reactive surface. Additionally, these compounds are biomimetic and show
then a high biocompatibility. These considerations thus made of nanocrystalline apatites particularly
well-suited systems in view of biomedical applications. Although most envisioned applications are
related to bone engineering, the exceptional reactivity of these materials have also lately attracted
attention in other biomedical fields such as medical imaging.
In this field, imaging contrast-enhancing effects by way of luminescence has been considered in the
last few years, in particular using lanthanide doping, especially with europium or terbium ions [311–
315]. Generally speaking, lanthanide-based phosphors have indeed been used for many years in the
field of optical devices [316–318] andmore recently formedical applications [319–322]. In fact, systems
based on luminescent lanthanide ions present several advantages over other luminescent probes: in
particular, they do not lead to photobleaching issues (unlike organic fluorescent dyes like fluorescein,
green fluorescent protein or rhodamine), nor to flickering effects as with quantum dots. Also,
lanthanide ions give rise to fluorescence properties characterized by narrow emission bandwidths,
high photochemical stability and a long fluorescence lifetime. Finally, different colors are available by
varying the luminescent center used (e.g. green Tb3þ, red Eu3þ, .).
Nanocrystalline calcium phosphate apatites doped with Eu3þ or Tb3þ have been prepared and
investigated [311–315], exploiting the ability of the apatite structure to accommodate many types of
ionic substituents. Some luminescence properties of Eu3þ-doped apatites were examined in several
works [323–327], unveiling the possibility to obtain a red fluorescent probe. The possibility to excite
Eu3þ ions at low energy (in or near the visible domain) is indeed suitable for studying biological tissues
without altering them.
The development of imaging nanoprobes in biology faces the issue of particle size, especially when
interactions with cells are foreseen, either in vitro or in vivo. In this regard, the development of
suspensions of nanoparticles present a mean size lower than 100 nm is generally sought for improving
cell internalization capabilities, increasing blood circulation time, and avoiding secondary detrimental
effects due to systemic inoculation. Recently, the preparation of colloidal suspensions of doped apatite
nanocrystals stabilized by a phospholipid moiety has been reported [314,315], including from easily
handled ionic salts, and nanoparticle sizes tailorable as needed in the range 30–100 nmwere obtained.
Interestingly, these systems were found to exhibit a high luminescence lifetime (of the order of
a millisecond), largely greater than the autofluorescence of biological materials, therefore opening
promising upcoming outcomes in the field of medical imaging, for example using time-resolved image
acquisition systems.
Luminescence imaging data using intrinsically non-luminescent calcium phosphate apatite
compounds but associated with a fluorescent dye have also been reported. For instance, NIR obser-
vations were made possible using associations of apatite with embedded NIR-emitting indocyanine
green ICG [328]. In this case, the authors reported that the particles could accumulate in xenograft
breast adenocarcinoma tumors in a nudemousemodel, and ex-situ tissue imaging enabled deep-tissue
NIR imaging of porcine muscle. Similarly, the encapsulation of other fluorophores has also been re-
ported (e.g. Cy3 amidite dye [329]). Also, quantum dot-conjugated hydroxyapatite has been prepared
[330], and preliminary in vivo data led to clear images from the hypodermic injected area at the
emission wavelength of 600 nm, and to NIR emission at 800 nm visualized after intravenous injection.
The above statements illustrate the potential use of apatite-based systems, especially with colloidal
formulations, in view of the preparation of novel, highly biocompatible nanoprobes for medical
imaging.
6. Concluding remarks and perspectives
The present review gathers general and more focused information on nanocrystalline apatitic-
based systems and their applications in the biomedical field, not only in relation to bone repair but
also to other broader domains such as drug delivery or medical imaging. A special attentionwas paid to
the surface properties of biomimetic apatite nanocrystals, and major differences with stoichiometric
HA were stressed. In particular, the presence (and extent) of a hydrated non-apatitic calcium-phos-
phate layer on the nanocrystals can be seen as a key factor that controls the interactions of biomimetic
apatite nanocrystals and surrounding fluids, especially in terms of ion exchange or adsorption of
organic molecules.
There are excellent perspectives for the development of biomimetic nanoparticles with new
applications based on the control of size, shape, and specific surface area, doping with new ions, even
beyond bone regeneration, for example to produce photoluminescent and/or magnetic resonance
imaging (MRI) contrast materials, tailoring of their surface properties by coating their surface with
specific molecules and ions, or by using them to produce multifunctional engineered nanoparticles. In
this respect recent advances have been done for example to produce hollow nanospheres having for
instance a thickness of 45 nm and internal cavities of 60 nm [331], and the development of apatite-
based colloids is in expansion [289]. The high specific surface area allows apatite nanoparticles to
load drugs and enables one to envision a delivery upon stimulations such as ultrasounds. An important
feature is the possibility to prepare multifunctional engineered nanoparticles by conjugation of
nanocrystalline apatites with biocompatible entities such as vitamins, aminoacids, phospholipid
derivatives or else monoclonal antibodies or antitumor drugs to be used for example in cancer
treatment or diagnosis. One important challenge for the success of these new applications will be the
scaling up of current methodologies to produce large amounts of nanoparticles with homogeneous
morphological bulk and surface physico-chemical properties. In all cases mentioned here, a detailed
physico-chemical characterization of the obtained materials should be seen as a major prerequisite.
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